




## The Department of Health and Human Services

### REPORT TO CONGRESS

### Pandemic Influenza Preparedness Spending

Prepared in Response to Request in  
Conference Report 109-359

 DATE 12/31/07  
Charles E. Johnson  
Assistant Secretary for Resources and Technology  
December 2007

**Report Language – Conference Report 109-359 – December 30, 2005**

*"The conferees direct the Secretary to provide on a semi-annual basis to the House and Senate Appropriations Committees a report identifying the disbursements of funds received under this heading and a listing of the governments, companies and organizations that received funding. The report should include the amount and purpose of each grant or other form of assistance. Finally, the report should include the cumulative obligations by activity of the funds made available under this heading for pandemic preparedness, as well as any remaining unobligated balances."*

AND

*"The conferees direct the Secretary of Health and Human Services to provide the Committees on Appropriations with quarterly reports on the expenditure of the funds provided for the Food and Drug Administration in this Act for pandemic influenza preparedness. The reports shall also include details on any reimbursements received by the agency from any other federal agencies for expenses incurred for pandemic influenza preparedness. The first report shall be transmitted no later than February 15, 2006."*

**Introduction**

This report is an update to the previous reports to Congress that were provided in June and December 2006 and in June 2007. This report covers all activities from December 2005 to December 2007. The report covers the pandemic influenza funding provided in both the December 2005 emergency supplemental appropriations bill (PL 109-148) and the June 2006 emergency supplemental appropriations bill (PL 109-234).

In August 2005, animal outbreaks of highly pathogenic H5N1 had been reported in twelve countries around the world with 112 total human cases confirmed in four of those countries. Just over two years later in December 2007, the number of countries confirming animal outbreaks has jumped to 61, with 346 total human cases confirmed in fourteen of those countries. While the majority of human cases to date can be attributed to exposure to infected poultry, and sustained human-to-human transmission has not been observed, the human infections have been severe. Overall, 62 percent of human cases have been fatal. History shows that the mortality rate of a human pandemic virus is not likely to be this high. However, even a two percent case-fatality rate, as was seen in the 1918 pandemic, would constitute a public health catastrophe. Once a pandemic begins, time will be a critical factor in our ability to accomplish the necessary production and delivery of vaccines and other medical countermeasures required to mitigate the pandemic.

The threat associated with the ongoing occurrence of human cases and animal outbreaks must not be dismissed. Over the past two months, the delayed notification of a cluster of suspect human cases of H5N1 in Pakistan led to the international travel of an individual that had been exposed to H5N1. The exposure was discovered when the person requested medical attention following his arrival in New York State. Though this case was quickly

found to be negative, it exposed the threat posed by the influenza virus and the need for continued cooperation with our international partners to detect and contain the virus. It also highlighted the importance of our efforts to develop the capability for rapid laboratory confirmation of suspect cases and contacts. Continued progress in virus and disease detection, enhancement of surveillance systems, and other aspects of pandemic preparedness are critical to our national security.

On November 1, 2005, the President requested a total of \$7.1 billion in emergency funding for pandemic influenza preparedness activities, of which \$6.7 billion was for implementation of the *HHS Pandemic Influenza Plan*. This funding was requested in FY 2006 to fund a staged three-year preparedness effort to ensure the Nation could effectively respond in the event of a pandemic. In December 2005, Congress appropriated \$3.3 billion in emergency funding for HHS in an FY 2006 supplemental, for the first year of the *HHS Pandemic Influenza Plan*. In June 2006, Congress appropriated \$2.3 billion for HHS in emergency funding in a second FY 2006 supplemental for the second year of the HHS Plan. HHS has used these funds to advance the Nation's pandemic preparedness by expanding and diversifying domestic vaccine production and surge capacity; enlarging H5N1 pre-pandemic vaccine and antiviral drug stockpiles; supporting advanced development of cell culture and antigen sparing influenza vaccines and new antiviral drugs; supporting advanced development of point-of-care clinical diagnostics; stockpiling medical supplies and ventilators; improving State and local preparedness; expanding risk communication efforts; enhancing FDA's regulatory science base; and expanding surveillance, research, and international collaboration efforts of CDC, NIH, and the HHS Office of Global Health Affairs.

HHS has made tremendous strides in enhancing pandemic preparedness for our Nation and our international partners. As of December 2007, HHS has obligated approximately \$4.3 billion in pandemic influenza funds and has unobligated balances totaling \$1.2 billion from the two emergency supplemental appropriations bills. HHS has obligated an additional \$1.3 billion since the June 2007 report. This report describes key accomplishments on our path to pandemic preparedness and details how appropriated funds have been spent to date.

The FY 2008 Appropriations bill did not include the \$870 million requested by the President for the next phase of the HHS Pandemic Influenza Plan. This funding was intended to **uphold our funding commitments for additional obligations**. Many of the advanced development contracts have made commitments pending successful completion of milestones. One example is the advanced development of cell-based seasonal and pandemic influenza vaccines, in which each contractor must demonstrate adequate product safety and efficacy in phase II clinical studies and appropriate domestic manufacturing facility biosecurity. Another example is the advanced development of an antigen-sparing pandemic influenza vaccine, in which successful completion of phase I trials of the candidate vaccine must be obtained.

The currently planned allocations of funding by category included in the table below and in this report are based on the best scientific evidence and technical information available. HHS may reallocate these funds in the future should new scientific or technological opportunities or contracting realities necessitate modification in order to best advance our Nation's pandemic response capabilities. Pandemic influenza funding has also been used to support administrative expenses necessary to achieve the goals of the *HHS Pandemic Influenza Plan*.

<b>FY 2006 Pandemic Influenza Supplemental Funding</b>			
<i>(dollars in millions)</i>			
	<b>December 2005</b>	<b>June 2006</b>	<b>Total</b>
Vaccines.....	1,781	1,452	3,233
Antivirals.....	731	350	1,081
Medical Supplies.....	162	8	170
State and Local Preparedness.....	350	250	600
International Collaboration.....	125	54	179
Other Domestic Activities.....	138	138	276
Risk Communications.....	33	18	51
<b>Total, HHS.....</b>	<b>3,320</b>	<b>2,270</b>	<b>5,590</b>

### **Vaccine**

While all efforts will be made to detect and contain an emerging pandemic, the infectiousness and short incubation time of influenza viruses make preventing a pandemic unlikely. Most of our preparedness efforts are designed to mitigate the consequences of a global pandemic. The one exception is in the area of vaccine development. An effective vaccine could convert population susceptibility into population immunity and alter the course of an emerging pandemic.

A key goal of the *HHS Pandemic Influenza Plan* is to provide pandemic influenza vaccine to every American within six months of detection of sustained human-to-human transmission of pandemic influenza. To achieve this goal, HHS is investing in the expansion of vaccine manufacturing capacity (egg- and cell-based), the advanced development of new cell-based vaccines, antigen-sparing technologies, and the establishment and maintenance of pre-pandemic vaccine stockpiles.

#### *Accomplishments to Date:*

- Over the past three years, HHS has established a pre-pandemic influenza vaccine stockpile of H5N1 vaccine. As of December 2007, HHS has procured 13 million courses of pre-pandemic vaccine. Recognizing the continuous evolution of the H5N1 virus, stockpile purchases include both clade 1 and clade 2 vaccines.
- In October 2007, HHS issued a Request for Proposals (RFP) for the advanced development of next generation recombinant influenza vaccines toward U.S. licensure that may shorten the timeline for production and release of pandemic influenza vaccine.



- In June 2007, HHS awarded \$133 million to sanofi pasteur and MedImmune for the retrofitting of existing domestic manufacturing facilities of U.S.-licensed biologicals for pandemic influenza vaccine production to increase domestic egg-based seasonal, pre-pandemic, and pandemic influenza vaccine production capacity and for warm-base manufacturing operations through new and converted facilities.
- In January 2007, HHS awarded three contracts totaling \$133 million to GlaxoSmithKline, Novartis and IOMAI for the advanced development of H5N1 influenza vaccines using antigen-sparing techniques toward U.S. licensure and expanded domestic vaccine manufacturing surge capacity. One contract may receive additional funding based upon successful completion of phase I trials.
- In May 2006, HHS awarded five contracts for over \$1 billion to GlaxoSmithKline, MedImmune, Novartis (formerly Chiron), Solvay, and Dynport (with Baxter) for support of advanced development of cell-based influenza vaccines toward U.S. licensure and expanded domestic vaccine manufacturing surge capacity. These contracts are designed to establish U.S. production of at least 240 million courses of cell-based pandemic vaccine within six months of the emergence of a pandemic influenza virus.

As of December 15, 2007, HHS has obligated \$2.3 billion out of the \$3.2 billion allocated between the two supplemental appropriations bills for vaccine-related activities.

### **Antiviral Drugs**

Another key goal in the *HHS Pandemic Influenza Plan* is to ensure the availability of antiviral treatment courses for 25 percent of the U.S. population. The Federal government and States will accomplish this goal by together purchasing a total of 81 million courses of antiviral drugs.

In December 2007, HHS completed the 50 million course Federal antiviral stockpile purchase for the Strategic National Stockpile. The majority of that stockpile, 44 million courses, will be allocated based on population to the States and other public health emergency preparedness partners. In addition, the Federal government has stockpiled six million treatment courses to attempt to mitigate localized outbreaks of pandemic influenza, bringing the Federal stockpile total to 50 million treatment courses.

Almost all States have taken advantage of a Federal contracting subsidy that allows States to purchase a total of 31 million treatment courses of antiviral drugs by leveraging Federal "best price" contracts and a subsidy of up to 25 percent of the Federal contract price. States also purchased antiviral drugs using these Federal contracts with unsubsidized funds, allowing them to purchase additional doses beyond what was initially projected.

At present, there is a single class of antiviral drugs on the market that would potentially be effective in a pandemic. The inherent nature of microbes is to evolve and develop resistance. For this reason, the HHS strategy has been to invest in next generation products in addition to securing currently available drugs.

*Accomplishments to Date:*

- In December 2007, HHS completed the 50 million course Federal antiviral stockpile purchase of Tamiflu and Relenza, completing the Federal stockpile goal. All purchases will be delivered to the SNS by the end of FY 2008. The Federal antiviral stockpile includes pediatric formulations of influenza antiviral drugs, consistent with provisions related to protecting children and other at-risk populations in the Pandemic and All Hazards Preparedness Act.
- In January 2007, HHS awarded a contract for \$102 million for the advanced development of a new neuraminidase-inhibitor class of influenza antiviral drugs for life-threatening cases of severe or pandemic influenza in hospitals. Phase II clinical studies for this drug were completed in September 2007, and phase III clinical studies will begin during the 2007-2008 Northern hemisphere influenza season.
- To date the States have purchased 19 million treatment courses of Tamiflu and Relenza for pandemic stockpiles, of which 17 million treatment courses have been delivered. Plans from all States have been received to utilize the Federal subsidy allocations to purchase at least 31 million treatment courses by July 2008.

As of December 15, 2007, HHS has obligated \$936 million out of the \$1.1 billion allocated between the two supplemental appropriations bills for antiviral-related activities. HHS has expended all funds allocated for direct Federal stockpile of antiviral drugs.

**Medical Supplies**

HHS is expanding medical infrastructure and response capacity during an influenza pandemic by stockpiling medical supplies for distribution to States in the event of a pandemic. HHS' plan is to purchase personal protective equipment (e.g., surgical masks and respirators) to help reduce exposure to the pandemic influenza virus and reduce the spread of the disease. In addition, HHS plans to purchase and stockpile ventilators to provide assistance in patient breathing to the critically ill. Other purchases include intravenous antibiotics, syringes and needles, and non-pharmaceuticals.

*Accomplishments to Date:*

- HHS has purchased approximately 156 million masks and respirators, for approximately \$49 million. This includes 104 million N95 respirators and 52 million surgical masks.

- HHS has obligated \$100 million for the purchase of ventilators, syringes, and IV antibiotics for potential distribution in case of an influenza pandemic.

As of December 15, 2007, HHS has obligated \$161 million out of the \$170 million allocated between the two supplemental appropriations bills for medical supplies.

### **State and Local Preparedness**

A pandemic will be widespread and will affect many areas of the country simultaneously. Preparedness is a shared responsibility and must involve every level of government. State and local governments will play a critical role in responding to a pandemic. HHS has been working with States and local communities to update their pandemic influenza plans and to ensure that they evaluate their plans through exercises. HHS has also provided States additional information on exercise requirements related to mass vaccination and non-pharmaceutical interventions and distribution of antiviral drugs and other countermeasures, specifically school closures. HHS has conducted a pandemic influenza summit in every State and Territory. These summits brought together HHS leadership with State leadership, health professionals, schools, and the private sector to discuss State and community preparedness issues.

#### *Accomplishments to Date:*

- On August 30, 2007, ASPR awarded \$75 million to State and local grantees to increase medical surge capacity, establish stockpiles of critical medical equipment and supplies, support planning and development of alternate care sites, and conduct medical surge exercises for pandemic influenza.
- On July 17, 2007, CDC awarded \$175 million to assist public health departments in their pandemic influenza planning efforts. The remaining \$24 million appropriated for State and local preparedness will be awarded to States on a competitive basis this fiscal year.
- In 2006, HHS awarded a total of \$325 million for State and local preparedness and conducted over 50 State pandemic influenza summits.
- HHS has partnered with the National Governors Association (NGA) to assist States in upgrading their pandemic influenza preparedness capabilities. In advance of participation in regional exercises, NGA is assisting States in updating plans according to current HHS guidance. NGA is holding up to ten meetings that focus on State pandemic preparedness using table-top exercises to test intergovernmental and interstate coordination. NGA is assisting States in updating plans to address gaps and new benchmarks identified through the regional exercises. Finally, NGA is in the process of developing a best practices summary of State pandemic influenza preparedness activities.

As of December 15, 2007, HHS has obligated \$576 million out of the \$600 million available between the two supplemental appropriations bills for State and local preparedness. HHS will obligate the remainder of these funds this fiscal year.

### **International Collaboration**

HHS is actively engaged with countries around the world to help them prepare for the possibility of a pandemic influenza outbreak, and to help minimize and contain the impact of an outbreak should one occur. HHS is collaborating with the U.S. Departments of State and Agriculture, as well as the U.S. Agency for International Development (USAID) to enhance preparedness in other countries by providing training, direct assistance, supplies, reagents and technical support to the World Health Organization (WHO), ministries of health and non-governmental organizations. HHS is also actively engaged with the Department of Defense, through entities such as the U.S. Naval Medical Research Units (NAMRUs).

#### *Accomplishments to Date:*

- HHS deploys teams of experts to help investigate suspected human cases of infection with avian influenza A wherever and whenever they are needed. To date, HHS staff have assisted WHO and ministries of health in H5N1 investigations in Turkey, Nigeria, Romania, Djibouti, Indonesia, Ghana, China, Laos, Vietnam, South Sudan, Thailand, and Pakistan. As part of these efforts, HHS scientists investigate clusters of H5N1 cases to rule out the occurrence of efficient human-to-human transmission, which would signal the emergence of a potential pandemic influenza strain.
- If a pandemic occurs, 517 HHS staff are trained and ready for deployment overseas. They include 234 current (or recently graduated) EIS Officers, 50 international field staff, 20 Career Epidemiology Field Officers currently stationed in U.S. States and cities, and 213 middle-to-senior level CDC internal staff persons.
- 112 countries in all six WHO regions have participated in HHS-sponsored regional response workshops that include training for country-level rapid response teams. The Global Disease Detection Centers in Guatemala, Kenya and Thailand maintain fully equipped regional rapid response teams, as well as stockpiles of personal protective equipment and antiviral medications for use during the initial wave of a pandemic. HHS has supported establishment of additional regional rapid response teams in China, Egypt, India, Indonesia, and Kazakhstan.
- 68 countries in all six WHO regions have participated in HHS-sponsored regional and country-level laboratory workshops on molecular diagnosis of avian influenza. In March 2007, the new Laos National Influenza Laboratory, established with on-site assistance from HHS, identified a human case of H5N1 without outside assistance and sent the specimen to a WHO Collaborating Center

for confirmatory testing. This is a major milestone in the development of capacity for pandemic influenza detection and response in a priority country.

- HHS has stationed CDC Influenza Coordinators at Global Disease Detection Centers in China, Egypt, Guatemala, Kenya and Thailand, and has stationed 16 CDC staff responsible for influenza activities in Cambodia, Republic of the Congo, Egypt, India, Indonesia, Kazakhstan, Laos, Peru, Philippines, Sweden, Switzerland, Vietnam, and the United Kingdom.
- HHS is working with CARE International on community-level avian influenza awareness campaigns and health promotion activities in Cambodia, Indonesia, Laos, and Vietnam.
- HHS continues to work with ministries of health to support Field Epidemiology Training Programs (FETPs) in Brazil, Central America, Central Asia, China, Egypt, Jordan, India, and Thailand, and Field Epidemiology and Laboratory Training Programs (FELTPs) in Kenya and South Sudan. Two new FELTPs—in Pakistan and South Africa—were established in 2006, in partnership with USAID, and planning is underway to establish new FETPs in Vietnam and Cambodia. Trainees and staff from FETP-Thailand participated in field investigations of suspect human H5N1 cases in Cambodia and Thailand; trainees from FELTP-Kenya participated in H5N1 field investigations in Nigeria and South Sudan; and trainees and graduates of FETP-China participated in H5N1 field investigations in several Chinese provinces. The new FELTP in Pakistan has instituted sentinel surveillance for influenza.
- NAMRU-3 has an Interagency Agreement with HHS to provide technical assistance with influenza diagnostics and surveillance to: Afghanistan, Armenia, Azerbaijan, Bulgaria, Macedonia, Morocco, Romania, Ukraine and Uzbekistan. NAMRU-3 also provides influenza support to WHO Regional Office for the Eastern Mediterranean countries (including Djibouti, Egypt, Jordan, Oman, Pakistan, Saudi Arabia and Syria) and to Georgia, Kazakhstan, and Kyrgyzstan. NAMRU-3 also assists NAMRU Kenya in collaboration with the CDC Global Disease Detection Center in Nairobi, in conducting influenza surveillance in Kenya. Beginning in late 2007, NAMRU-3 has also provided assistance to Tajikistan and Turkmenistan.
- HHS is promoting international use of non-pharmaceutical interventions—public health measures other than vaccination and drug treatment—through regional response workshops and exercises, participation in WHO consultations and diplomatic efforts, and outreach to the private sector via the Asia-Pacific Economic Cooperation forum. Non-pharmaceutical interventions may be used for rapid containment of an incipient pandemic (i.e., extraordinary international efforts to rapidly contain a local outbreak caused by an efficiently-transmitted novel influenza virus) and for community mitigation (i.e., community-based efforts to mitigate illness and social disruption once a pandemic is widespread).

Non-pharmaceutical interventions include isolation of ill persons, voluntary home quarantine of household contacts of ill persons, dismissal of classes for school-age children, and institution of work-place and community social distancing measures for adults.

- HHS has helped enhance global capacity for clinical management and infection control during a pandemic by describing the clinical manifestations of the first identified cases of human H5N1 infection; developing hospital infection control training materials and supporting training activities in Cambodia, Laos, Kenya, Thailand, and Vietnam; and by assisting WHO with development and field-testing of international guidelines on respiratory hygiene and cough etiquette for use in healthcare settings.
- NIH awarded a contract for \$8 million to expand the Southeast Asian Influenza Clinical Research Network, a collaborative partnership of hospitals and institutions in Indonesia, Thailand, the United Kingdom, the United States, and Vietnam. The funding is accelerating the establishment of additional clinical research sites whose mission is to advance the scientific knowledge and management of human influenza through research into the development of therapeutics, diagnostics and vaccines. These clinical research sites are currently supporting one clinical protocol and have two others in development to evaluate the effective use of Tamiflu and another antiviral drug in countering severe seasonal or avian influenza.

As of December 15, 2007, HHS has obligated \$172 million out of the \$179 million allocated between the two supplemental appropriations bills for international collaboration. The remaining \$7 million will be used to continue to carry out activities begun in FY 2006 through FY 2008.

### **Other Domestic Activities, including Risk Communications**

HHS is working on the domestic front to enhance surveillance through partnerships with State and local laboratories. HHS is working to increase and expand the capacity of quarantine stations, enhance laboratory capacity at CDC, and improve diagnostic tools. The development of rapid diagnostics will facilitate the speed and accuracy with which scarce countermeasures will be distributed. Risk communication strategies are being developed and implemented. These activities will allow HHS to build the domestic capacity needed to detect and respond to a pandemic early and effectively.

#### *Accomplishments to Date:*

- CDC has developed and refined the Countermeasure and Response Administration (CRA) system for tracking pre-pandemic and pandemic influenza vaccine doses administered. CDC is testing the CRA system using seasonal influenza vaccination clinics in States for the 2007-2008 influenza season as a proxy for tracking doses administered during an influenza pandemic.



Additionally, work is being done to enhance the surge capacity of the Vaccine Adverse Events Reporting System (VAERS), and to assess the effectiveness of seasonal influenza vaccine. This assessment will provide a platform for conducting pandemic vaccine effectiveness studies.

- In Spring 2007, CDC opened two additional **quarantine** stations in Dallas and Philadelphia, bringing the total number of stations to 20. HHS continues to evaluate community mitigation strategies for pandemic influenza. Through cooperative agreements with six national and two international influenza research centers, CDC has supported applied research on non-pharmaceutical interventions for seasonal influenza. The outcomes of these studies will provide valuable information for both seasonal and pandemic influenza preparedness.
- Funds have been provided to several laboratories at CDC to conduct diagnostic tests, RNA sequencing studies, and antigenic characterization of influenza viruses during an influenza pandemic when the **lab capacity** of the Influenza Division would be overwhelmed. HHS funded StarLIMS to continue the facilitation and implementation of the Laboratory Information Management System that will facilitate the rapid, real time transmission of laboratory information regarding influenza tests and results between CDC, State and local health departments and international laboratory partners.
- CDC has collected and characterized over 5,000 influenza viruses needed for U.S. and global strain selection for seasonal influenza vaccine (in collaboration with FDA and WHO) for a **library of pandemic reference strains**. Seasonal, avian and other novel influenza viruses are evaluated for changes that may indicate drift away from current vaccines or for changes in transmission characteristics. The first H5N1 clade 2 pandemic influenza vaccine candidate has been developed for distribution to vaccine manufacturers. Over 2,000 influenza viruses have been characterized for resistance to antiviral drugs, leading HHS to issue recommendations to clinicians to use only oseltamivir or zanamivir to treat patients with influenza.
- Through the development of its **diagnostic reagent stockpile**, CDC has determined surge needs for maintaining diagnostic testing before and during a pandemic, and has developed and distributed influenza detection kits to over 200 WHO reference laboratories and other laboratories in countries around the globe. CDC has evaluated the proficiency of laboratorians conducting influenza testing in the U.S. and abroad.
- In December 2007, the first of two prototype point-of-care influenza **rapid test** devices was submitted for independent evaluation; the second is expected in March 2008. Both new devices are being developed under government-funded contracts with commercial test manufacturers. These devices will allow doctors and other health professionals to diagnose avian influenza rapidly and easily in a



clinic office or other outpatient setting. FDA approval is anticipated in 2008-2009.

- In November 2007, CDC completed clinical evaluation of the new CDC 5-target PCR **rapid diagnostic** test for avian and seasonal influenza. This high-throughput assay test will be submitted to FDA for approval this January. The test will be used in all U.S. public health laboratories and internationally at WHO reference laboratories. It will serve as the gold-standard test for confirming the first cases of avian or potentially pandemic influenza.
- In January 2008, a CDC technical evaluation panel will make a determination on solicited proposals for development of a new, bench top laboratory-based **rapid influenza test** for use in community hospitals. This device will allow hospitals to rapidly test multiple patients at a time for avian or potentially pandemic influenza. An award of \$13.5 million to successful offerors is anticipated for March 2008.
- In November 2007, HHS initiated a series of public engagement meetings to examine public views and values with respect to vaccine prioritization. In November, public engagement meetings were held in Hendersonville, NC and Milwaukee, WI. A web dialogue took place in December. Additionally, members of the public can comment on the draft guidance via [pandemicflu.gov](http://pandemicflu.gov). Public input is an important part of HHS' pandemic planning efforts.
- In June 2007, HHS hosted a Pandemic Flu Leadership Forum and blog to support its public education campaign designed to raise awareness of pandemic influenza and the steps individuals and families can take now to prepare. The campaign, "*Take the Lead: Working Together to Prepare Now*" encourages local community leaders, representing the business community, faith-based and civic communities, and health care providers to share pandemic planning information with their employees, members and patients.

As of December 15, 2007, HHS has obligated \$217 million out of the \$332 million allocated between the two supplemental appropriations bills for these domestic activities.

### **Food and Drug Administration (FDA)**

FDA's efforts to enhance its infrastructure and provide personnel and expertise in the essential clinical, product and manufacturing areas are vital to support new vaccine development. FDA has expended funds provided through the December 2005 emergency supplemental appropriations bill, and will not be included in future reports.

*Accomplishments in the FDA Center for Biologics Evaluation and Research (CBER) include:*

- Approval for the first U.S. vaccine for humans against the avian influenza virus, H5N1.

- FDA issued two guidance documents that outline the regulatory pathways for rapid development and approval of safe and effective vaccines for both seasonal and pandemic influenza. The guidance documents entitled, "Guidance for Industry, Clinical Data Needed to Support the Licensure of Seasonal Inactivated Vaccines," and "Guidance for Industry, Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines," will help to increase the supply of influenza vaccines and development of new approaches to vaccine production.
- FDA implemented innovative approaches to develop and test monitoring systems for vaccine safety through projects with Harvard, Pilgrim Health Care, the CDC, United Health Care, as well as the Centers for Medicare and Medicaid Services and Department of Veterans Affairs. These systems will be used to expand and test the ability to perform rapid analysis of healthcare databases for use during an influenza pandemic or other urgent situation.
- FDA developed a pandemic information technology (IT) plan for readiness to protect key review and laboratory testing informatics capacities and assure emergency access to data and communications.
- FDA continues to provide active consultation to WHO in developing policy on a WHO Global Vaccine Stockpile and influenza vaccines strains for the Southern Hemisphere, and to evaluate and recommend potential pandemic influenza vaccine strains. FDA collaborated with the global community and WHO in the generation of appropriate H5 vaccine reference strains and seasonal influenza reference strains and reagents.
- In collaboration with CDC, FDA established an influenza microneutralization assay for evaluation of immunity to seasonal and avian influenza vaccines. Study plans were finalized for an international collaborative effort to evaluate an H5N1 international standard.

*Accomplishments in the FDA Office of Regulatory Affairs (ORA) include:*

- FDA's Office of Criminal Investigations continues efforts to engage individuals and companies selling pandemic influenza products over the internet. Undercover purchases are made during continuing investigations targeting individuals and Internet websites that promote the sale of counterfeit Tamiflu and fraudulent pandemic flu medications and products. Daily internet surveillance is conducted to detect counterfeit and fraudulent bird flu products. Sixty warning letters have been issued to date.
- ORA's biologics inspectional force, with support from CBER, completed annual inspections of influenza virus vaccine manufacturing facilities and engaged in appropriate compliance follow-up with manufacturers when inspections revealed

issues that could compromise a safe, plentiful supply of seasonal or pandemic influenza vaccine.

- In addition, ORA (along with the Center for Drug Evaluation and Research, Office of the Chief Counsel, and the Office of the Commissioner) continues to discuss third party models as a way to assess and add confidence in the storage conditions of FDA regulated products being stored in various locations that support emergency national medical product stockpiles. It is expected that these activities will make more efficient use of FDA resources and work to ensure that these products are safely stored and maintained for use in a potential emergency.

FDA has obligated all of the \$20 million in emergency supplemental funds on pandemic influenza activities.

**Department of Health and Human Services**  
**Report to Congress**  
**Pandemic Influenza**  
*(\$ in millions)*

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
<b>VACCINE FUNDING</b>	<b>1,781.0</b>	<b>1,452.0</b>
<b>ACHIEVE CAPACITY AND/OR BUY COURSES FROM EGG-BASED MANUFACTURER</b>	<b>511.0</b>	<b>300.0</b>
<i>ASPR/CDC Contracts issued for the acquisition of H5N1 vaccine for pre-pandemic stockpile:</i>		
Sanofi Pasteur & Chiron (contracts issued in 2005)	80.0	
<i>ASPR Contracts issued for the acquisition of H5N1 vaccine for pre-pandemic stockpile:</i>		
GlaxoSmithKline (contract for the acquisition of H5N1 clade 2 vaccine in November 2006)	40.6	
Novartis (contract for the acquisition of H5N1 clade 2 vaccine in November 2006)	41.0	
Sanofi Pasteur (contract for the acquisition of H5N1 clade 2 vaccine in November 2006)	117.9	
<i>ASPR Modifications to contracts for additional doses, replenishment, and storage and stability:</i>		
GlaxoSmithKline (modifications to existing contract for additional manufacturing of bulk H5N1 vaccine in July 2007)	22.6	37.6
GlaxoSmithKline (modifications to existing contract for additional manufacturing of bulk H5N1 vaccine in July 2007)	36.5	60.8
Novartis (modifications to existing contract for additional manufacturing of bulk H5N1 vaccine in August 2007)	31.9	53.2
Novartis (modifications to existing contract for additional manufacturing of H5N1 vaccine in August 2007)	5.9	
Sanofi Pasteur (modifications to existing contract for additional manufacturing of bulk H5N1 vaccine in July 2007)	75.5	125.8
Sanofi Pasteur (modifications to existing contract for additional manufacturing of bulk H5N1 vaccine in August 2007)	9.8	
Sanofi Pasteur (modifications to existing contract for storage and stability studies in September 2006)	4.8	
Sanofi Pasteur (modifications to existing contract for storage and stability testing in September 2007)		2.0
Sanofi Pasteur (modifications to existing contract for storage and stability testing in September 2007)		4.0
Sanofi Pasteur (modifications to existing contract for storage and stability testing in October 2007)		4.7
Sanofi Pasteur (modifications to existing contract for additional manufacturing of bulk and final container of H5N1 vaccine in September 2007)	4.4	1.4
Sanofi Pasteur (modifications to existing contract for additional studies under egg supply contract in September 2007)		0.5
<b>Cumulative Obligations, Achieve Capacity and/or Buy Courses from Egg-based Manufacturers</b>	<b>470.8</b>	<b>289.9</b>
<i>Unobligated Balances, Achieve Capacity and/or Buy Courses From Egg-based Manufacturers</i>	<i>40.2</i>	<i>10.1</i>
<b>ACCELERATE CELL-BASED VACCINE</b>	<b>1,010.0</b>	<b>842.0</b>
<i>ASPR Contracts issued May 1, 2006 for the advanced development of cell-based pandemic influenza vaccines for domestic licensure &amp; manufacturing:</i>		
DynPort	41.0	
GlaxoSmithKline	274.8	
MedImmune	169.5	
Novartis/Chiron (includes \$159,000 additional funding for storage and stability)	220.5	
Solvay	298.6	
<i>ASPR Modifications to contracts:</i>		
Dynport (modification to existing contract in October 2007)		201.3
<b>Cumulative Obligations, Accelerate Cell-Based Vaccine</b>	<b>1,004.3</b>	<b>201.3</b>
<i>Unobligated Balances, Accelerate Cell-Based Vaccine</i>	<i>5.7</i>	<i>640.7</i>
<b>RETROFIT OF FACILITIES FOR EMERGENCY PRODUCTION OF VACCINE</b>	<b>100.0</b>	<b>200.0</b>
<i>ASPR Contracts issued June 4, 2007 for the retrofitting of facilities for the emergency production of influenza vaccine:</i>		
MedImmune		55.1
Sanofi Pasteur		77.4
<b>Cumulative Obligations, Retrofit of Facilities</b>	<b>0.0</b>	<b>132.5</b>
<i>Unobligated Balances, Retrofit of Facilities</i>	<i>100.0</i>	<i>67.5</i>
<b>ADVANCED DEVELOPMENT OF ANTIGEN-SPARING TECHNIQUES</b>	<b>140.0</b>	<b>110.0</b>
<i>ASPR Contracts issued January 4, 2007 for the advanced development of antigen-sparing techniques:</i>		

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
GlaxoSmithKline	63.3	
IOMAI	14.5	
Novartis	54.8	
<b>Cumulative Obligations, Advanced Development of Antigen-Sparing Techniques</b>	<b>132.6</b>	<b>0.0</b>
<i>Unobligated Balances, Advanced Development of Antigen-Sparing Techniques</i>	<i>7.4</i>	<i>110.0</i>
<b>FDA ACTIVITIES</b>	<b>20.0</b>	<b>0.0</b>
Contracts for IT Development and Maintenance, Technical and Contractual Support Services, Renovations for Quality Controlled Labs, Fraudulent Flu Awareness Campaign; Events Mgmt., and Publications	7.9	
Purchase of Lab Supplies, i.e. Biological Materials and Chemicals; Personal Protective Emergency Equipment/Materials for Field Investigators; Medical and Scientific Lab Equipment, i.e. Centrifuge, Gas Chromatograph System, Voltammetric Digital Analyzer System, Spectrometer; IT Equipment	7.7	
Program Management Costs (salaries and benefits; rent; travel and transportation; training; meetings and workshops; and miscellaneous)	4.4	
<b>Cumulative Obligations, FDA</b>	<b>20.0</b>	<b>0.0</b>
<i>Unobligated Balances, FDA</i>	<i>0.0</i>	<i>0.0</i>
<b>PROGRAM MANAGEMENT</b>		
FY 2006	8.6	
FY 2007	12.8	
FY 2008	1.3	
<b>Cumulative Obligations, Program Management</b>	<b>22.7</b>	<b>0.0</b>
<i>Unobligated Balances, Program Management</i>	<i>0.0</i>	<i>0.0</i>
<b>Cumulative Obligations, Vaccine</b>	<b><u>1,650.3</u></b>	<b><u>623.7</u></b>
<i>Unobligated Balances, Vaccine</i>	<i>130.7</i>	<i>828.3</i>
<b>ANTIVIRAL DRUGS FUNDING</b>	<b><u>731.0</u></b>	<b><u>350.0</u></b>
<b>FEDERAL STOCKPILE &amp; CONTAINMENT EFFORT</b>	<b>391.8</b>	<b>350.0</b>
<i>CDC Contracts to procure a supply of treatment courses of antiviral drugs (Roche's Tamiflu &amp; GSK's Relenza) for the Strategic National Stockpile:</i>		
Roche and GlaxoSmithKline (purchase of Tamiflu and Relenza)	391.8	350.0
<b>Cumulative Obligations, Federal Stockpile &amp; Containment Efforts</b>	<b>391.8</b>	<b>350.0</b>
<i>Unobligated Balances, Federal Stockpile &amp; Containment Efforts</i>	<i>0.0</i>	<i>0.0</i>
<b>SUBSIDIZE STATE PURCHASE OF ANTIVIRAL DRUGS</b>	<b>170.0</b>	<b>0.0</b>
<i>ASPR Contracts to allow States to purchase antiviral drugs (Roche's Tamiflu &amp; GSK's Relenza) at a subsidized Federal government price:</i>		
Roche (Federally subsidized purchase of Tamiflu in June 2006)	29.8	
GlaxoSmithKline (Federally subsidized purchase of Relenza in July 2006)	16.8	
Roche (Federally subsidized purchase of Tamiflu in September 2006)	29.8	
Roche (Federally subsidized purchase of Tamiflu in September 2007)	14.9	
<b>Cumulative Obligations, Subsidize State Purchase of Antiviral Drugs</b>	<b>91.4</b>	<b>0.0</b>
<i>Unobligated Balances, Subsidize State Purchase of Antiviral Drugs</i>	<i>78.6</i>	<i>0.0</i>
<b>ADVANCED DEVELOPMENT OF PROMISING ANTIVIRAL DRUGS</b>	<b>169.2</b>	<b>0.0</b>
<i>ASPR Contracts issued for the acquisition of promising antiviral drugs:</i>		
BioCrist contract awarded for Peramivir, a promising antiviral drug	102.7	
<b>Cumulative Obligations, Advanced Development of Promising Antiviral Drugs</b>	<b>102.7</b>	<b>0.0</b>
<i>Unobligated Balances, Advanced Development of Promising Antiviral Drugs</i>	<i>66.5</i>	<i>0.0</i>
<b>Cumulative Obligations, Antiviral Drugs</b>	<b><u>585.8</u></b>	<b><u>350.0</u></b>
<i>Unobligated Balances, Antiviral Drugs</i>	<i>145.2</i>	<i>0.0</i>
<b>MEDICAL SUPPLIES (PPE, VENTILATORS, ETC.) FUNDING</b>	<b><u>162.0</u></b>	<b><u>8.0</u></b>
<i>CDC Contracts issued for the acquisition of medical supplies:</i>		
Purchase of 62.5 million N-95 respirators for potential distribution to affected areas in case of an influenza pandemic.	50.0	
Purchase of ventilators, syringes, IV antibiotics, and storage & security from various suppliers	111.1	
<b>Cumulative Obligations, Medical Supplies</b>	<b><u>161.1</u></b>	<b><u>8.0</u></b>

Activities Funded with FY 2006 Emergency Funding:

FY 2006 December 2005  
Supplemental Obligations

FY 2006 June 2006  
Supplemental Obligations

*Unobligated Balances, Medical Supplies* 0.9 8.0

**STATE AND LOCAL PREPAREDNESS FUNDING** 350.0 250.0

*CDC Cooperative Agreements for special projects of national significance:*

National Governors Association (NGA)	1.0	0.0
Alabama	5.1	2.7
Alaska	1.6	0.8
American Samoa	0.3	0.1
Arizona	6.2	3.4
Arkansas	3.5	1.9
California	24.4	13.3
Chicago	3.6	1.9
Colorado	5.2	2.8
Commonwealth of North Mariana Islands	0.3	0.1
Connecticut	4.1	2.2
Delaware	1.8	0.9
District of Columbia	1.5	0.8
Federated States of Micronesia	0.3	0.2
Florida	16.8	9.2
Georgia	9.0	4.9
Guam	0.3	0.2
Hawaii	2.1	1.1
Idaho	2.3	1.2
Illinois	9.8	5.3
Indiana	6.6	3.6
Iowa	3.7	1.9
Kansas	3.5	1.8
Kentucky	4.7	2.5
Los Angeles	10.0	5.4
Louisiana	5.1	2.7
Maine	2.2	1.1
Maryland	6.0	3.2
Massachusetts	6.7	3.6
NYC Department of Health	8.3	4.5
Michigan	10.1	5.3
Minnesota	5.6	3.0
Mississippi	3.6	1.9
Missouri	6.2	3.3
Montana	1.8	1.0
Nebraska	2.6	1.4
Nevada	3.1	1.7
New Hampshire	2.2	1.1
New Jersey	8.8	4.8
New Mexico	2.7	1.4
New York State	11.0	5.9
North Carolina	8.7	4.7
North Dakota	1.6	0.8
Ohio	11.3	6.1
Oklahoma	4.2	2.2
Oregon	4.2	2.3
Pennsylvania	12.1	6.6
Puerto Rico	4.5	2.4
Republic of Palau	0.2	0.1
Republic of The Marshall Islands	0.3	0.1
Rhode Island	2.0	1.0
South Carolina	4.8	2.6
South Dakota	1.7	0.9
Tennessee	6.3	3.4
Texas	21.3	11.7
Utah	3.2	1.7

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
Vermont	1.6	0.8
Virgin Islands	0.3	0.2
Virginia	7.7	4.2
Washington	6.6	3.6
West Virginia	2.6	1.4
Wisconsin	6.0	3.2
Wyoming	1.5	0.7
<b>ASPR awards for State and local medical surge capacity:</b>		
Multiple Awardees		75.0
<b>Cumulative Obligations, State and Local Preparedness</b>	<b>326.0</b>	<b>250.0</b>
<i>Unobligated Balances, State and Local Preparedness</i>	<i>24.0</i>	<i>(0.0)</i>

<b>INTERNATIONAL ACTIVITIES FUNDING</b>	<b>125.0</b>	<b>54.0</b>
<b>INTERNATIONAL SURVEILLANCE</b>	<b>89.0</b>	<b>35.0</b>
CDC Personnel costs associated with International Surveillance	3.4	5.2
CDC International Travel for the Outbreak Monitoring Team and to assess preparedness	0.7	0.3
CDC Various contracts and IAAs under \$75,000 each	2.0	2.8
<b>CDC Grants to strengthen national capacity for surveillance &amp; containment:</b>		
Uganda Virus Research Institute	0.2	0.3
WHO		0.7
WHO/ South East Asia cooperative agreement with US CDC		0.7
WHO/ West Pacific cooperative agreement with US CDC		2.1
<b>CDC Grants and IAA's to support international surveillance, preparedness, detection, response, containment and risk communication activities:</b>		
Afghanistan	0.4	0.2
Argentina	0.9	0.5
Armenia	0.4	0.4
Bangkok	1.5	
Bangkok/Thailand Department of Medical Sciences for development of influenza surveillance networks	0.5	0.5
Bangladesh	0.4	0.2
Brazil	0.8	0.3
Cambodia	0.9	
CARE grant for global capacity through international NGO partner	0.1	0.5
CARE grant for Laos surveillance and lab activities	0.4	
COGH Business Services Unit	0.7	0.1
Columbia University Health Services in Rwanda grant for prevention and surveillance studies in Uganda mechanism used to fund and conduct influenza activities	0.2	
Commonwealth N. Mariana Islands Dept. of Public Health cooperative agreement used to fund regional reference laboratories for communicable and outbreak prone diseases including influenza		0.0
Cote d'Ivoire Ministry of Health and Public Hygiene for epidemiology and lab capacity building for surveillance and response		0.2
Cote d'Ivoire	0.3	
Directorate Gen/Dis Ctrl/Env Health grant for surveillance and response to avian and pandemic influenza		0.7
Ethiopia Federal Ministry of Health for preparedness and response to avian and pandemic influenza in the Federal Democratic Republic		0.2
Ethiopia JHPIEGO grant for surveillance and lab activities	0.3	
Ethiopian Health and Nutrition Inst. for surveillance and lab activities	0.1	
Georgia	0.4	0.3
Kenya	0.2	0.2
Laos	0.1	
Luanda Ministry of Health grant for surveillance and response to avian and pandemic influenza		0.3
Mexico	0.9	0.4
Morocco	0.6	0.4
NAMRU 2 IAA to support influenza surveillance activities	1.5	
NAMRU 3 IAA to support influenza surveillance activities	1.5	
Nigeria	0.3	0.2
PAHO	0.2	0.7
PAHO grant for coordination of comprehensive emerging infectious disease plans	0.9	



<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Peru</b>	0.8	0.4
<b>Public Health Foundation Enterprises</b> for epidemiology and lab capacity for infectious diseases in Russia	0.1	
<b>Romania</b>	0.6	
<b>Rwanda Treatment Research AIDS Center (TRAC)</b> mechanism used to fund and conduct influenza activities		0.3
<b>South African National Institute for Communicable Diseases</b>		0.1
<b>Tanzania</b>	0.1	
<b>Tanzania Ministry of Health/Social Welfare</b> grant for preparedness and response to avian and pandemic influenza		0.2
<b>Thailand Ministry of Public Health</b> for prevention and care of infectious diseases	0.1	
<b>Turkey</b>	0.1	
<b>Uganda Makerere Univ. Institute of Public Health</b> grant for prevention and surveillance studies in Uganda mechanism used to fund and conduct influenza activities	0.2	
<b>Ukraine</b>	0.6	0.4
<b>Universidad del valle de Guatemala</b> grant for Research in Human Infectious Diseases in Guatemala	0.03	
<b>University of Kinshasa</b> grant for surveillance and response to avian and pandemic influenza		0.2
<b>University of Maryland</b> grant for prevention and surveillance activities in Nigeria	0.1	
<b>Vietnam</b>	0.9	0.5
<b>WHO</b> grant to address emerging infectious diseases	6.3	3.0
<b>WHO/ AFRO</b> grant for surveillance and response to avian and pandemic influenza		0.9
<b>WHO/ Brazzaville</b>	0.8	
<b>WHO/ Denmark</b>	0.8	
<b>WHO/ Egypt</b>	2.1	0.8
<b>WHO/ Manila</b>	0.9	
<b>WHO/ New Delhi</b>	0.8	
<b><i>CDC Grants to support in-country development of influenza surveillance networks:</i></b>		
<b>China National Influenza Center</b> grant for development of influenza surveillance networks in China	0.4	
<b>Indian Council of Medical Research</b>	2.0	1.0
<b>Kazakhstan Ministry of Health</b> for development of influenza surveillance networks in Central Asia	0.3	
<b>Korean National Influenza Center</b> grant to develop influenza surveillance networks in Korea	0.2	0.2
<b>Ministry of Health, Mongolia</b>	0.6	0.4
<b>Ministry of Health, Indonesia</b>	1.3	0.7
<b>Ministry of Health, Malaysia</b>	0.7	
<b>Pakistan National Institutes of Public Health</b>	0.5	0.1
<b>Philippines Department of Health, National Influenza Center</b>	0.6	0.3
<b>Secretariat of the Pacific</b> grant for development of Pacific public health surveillance network		0.3
<b>Vietnam National Institute of Hygiene &amp; Epidemiology</b>		0.4
<b><i>CDC Grants and Contracts to support international staffing, including travel, logistical, technical, operational and professional support:</i></b>		
<b>Americom Government Services Inc.</b> contract for shared bandwidth services, AGS V-SAT generator, SmartPoint Terminal, Activation Fee, Travel and Site Survey	0.1	0.02
<b>ATA Services Inc.</b> for international program consultant	0.01	
<b>ATA Services Inc.</b> for salary and benefits	0.01	
<b>Bangkok International Surveillance:</b> Cable for consulting services in Bangkok (deobligated)	0.00	
<b>Bearingpoint, LLC</b> for technical staffing support	0.04	
<b>Booz Allen</b> for technical assistance	0.1	
<b>China Centers for Disease Control and Prevention</b> grant for development of influenza surveillance networks		0.5
<b>China Centers for Disease Control and Prevention</b> grant for prevention and surveillance activities	1.5	
<b>Comforce Technical Services</b> contract for a biologist	0.1	0.1
<b>Comforce Technical Services</b> contract for international technical and operational support	0.1	
<b>Comforce Technical Services</b> contract for International Technical Operational and Professional Support Services in Nigeria	0.3	
		0.1
<b>Comforce Technical Services</b> contract for International Technical Operational and Professional Support Services in Rwanda	0.2	
<b>Comforce Technical Services</b> contract for international technical, operational and professional support services	0.2	
<b>Comforce Technical Services</b> contract to support influenza surveillance activities in Nigeria	0.2	
<b>Comforce Technical Services</b> contract to support influenza surveillance activities in Tanzania	0.2	

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Countertrade Products, Inc.</b> contract for networking, computing and IT solutions	0.1	
<b>Countertrade Products, Inc.</b> for monitors	0.03	
<b>Emtec Federal Inc.</b> for standard desktops	0.1	
<b>Fisher Scientific Company LLC</b> contract for Dermathin latex gloves	0.01	
<b>McKing Consulting Corp.</b> contract for Outreach and Technical Assistance to International Communications Partners	0.1	
<b>National Associates, Inc.</b> for Management Analyst, Secretary	0.1	
<b>Northrop Grumman IT Services</b> for IT support	0.2	
<b>Policy Navigation Group LLC</b> for medical examination of aliens		0.4
	1.3	
<b>Professional and Scientific Associates, Inc.</b> contract for international travel & logistical support services		0.2
<b>Technology Management Company Inc.</b> contract for global logistics and administration	0.6	
<b>Technology Management Company Inc.</b> contract for technical and logistical support services	0.5	
<b>TEPHENET</b> grant for conference support	0.2	
<b>Thompson, Cobb, Bazilio &amp; Associates</b> contract for accounting and budgetary assistance concerning international surveillance activities	0.1	
<b>Total Solutions Inc.</b> contract for support services		0.03
<b>University of Maryland</b> grant for international staffing of prevention and surveillance activities	0.2	
<b>WPRO</b> grant to support influenza surveillance activities through international staffing	0.4	
<i>ASPR Supplement IAA's, Contracts, Grants and Supplement Grants to support international preparedness, detection, response, containment and risk communication activities:</i>		
<b>Bangkok Regional Site</b>	1.0	
<b>Bangladesh</b>	1.1	
<b>Cambodia</b> grant for development of influenza surveillance network overseas		0.3
<b>CDC IAA</b> to support response and containment activities through establishment of international stockpile	0.3	
<b>Central Asia Platform</b>	1.5	
<b>China</b>	0.4	
<b>Critical Outcome Evaluation</b> supplement grant to support preparedness and risk communication activities	0.1	
<b>Distance Learning: Surveillance &amp; Response</b> supplement grant to support preparedness and risk communication activities	0.1	
<b>FDA IAA</b> to support effective risk communication activities for regulatory preparedness workshops	0.5	
<b>Gorgas Memorial Institute (Panama)</b>	0.8	
<b>Gorgas Memorial Institute (Panama)</b>	2.5	
<b>India</b>	0.4	
<b>Indonesia</b>	1.9	
<b>Institute Pasteur Network (S.E. Asia and Africa)</b>	1.6	
<b>IOM</b> contract modification to fund meeting on influenza containment	0.1	
<b>Kenya Regional Site</b>	0.1	
<b>Kenya Regional Site</b>	1.0	
<b>Malaysia</b>	0.4	
<b>Mexico</b> supplement grant to assist in set-up of operations center	0.1	
<b>Mongolia</b>	0.4	
<b>Multinational Influenza Seasonal Mortality Study Group</b> supplement grant	0.1	
<b>Nigeria FELTP</b> supplement grant to support preparedness, surveillance and containment activities	0.2	
<b>NIH/NIGMS IAA</b> to Support Modeling of disease spread in SE Asia (MIDAS)	0.2	
<b>Outbreak Investigation Support</b> supplement grant to support preparedness, surveillance and containment activities	0.8	
<b>Pakistan</b>	0.4	
<b>Philippines</b>	0.4	
<b>RAND Contract Modification</b> for the Monitoring and Evaluation of Influenza Programs	0.5	
<b>Smithsonian Tropical Research Institute (Panama)</b> supplement grant	0.1	
<b>Smithsonian Tropical Research Institute Bird Monitoring</b> grant to support preparedness, surveillance and containment activities	0.2	
<b>South Africa Field Epidemiology and Lab Training Program (FELTP)</b> grant to support response and containment activities	0.4	
<b>Team PSA</b> contract for WHO/ASEAN/US Stockpile and Tri-lateral SPP coordination meeting	0.1	
<b>Ukraine</b>	0.4	
<b>University of Cape Town</b> supplement grant to support an infectious disease workshop	0.1	
<b>West Africa FELTP</b> supplement grant to support preparedness, surveillance and containment activities	0.2	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
WHO Egypt EMRO	0.5	
WHO Headquarters (In-Country Vaccine Development, Various Countries)	10.0	
WHO Specimen transport fund supplement grant to support preparedness, surveillance and containment activities	0.5	
WHO supplement grant to support response and containment activities through Pan Flu Rapid Response and Early Containment Project	1.0	
WHO-AFRO Brazza-ville	0.5	
WHO-AFRO Brazza-ville	0.4	
WPRO (Cambodia)	0.8	
WPRO (Laos, Vietnam)	0.3	
<b>OGHA Supplement Grants to support surveillance and detection activities:</b>		
Afghanistan	0.8	
Angola	0.8	
Brazil	0.1	
Iraq	0.4	
Kenya	0.2	
Libya	1.0	
Mexico	0.1	
REDI Center	2.1	
Turkey	0.3	
<b>OGHA Other:</b>		
ISTC & STCU IAA to support preparedness and risk communication activities	0.8	
OGHA Influenza Strategic Management Unit to support the management and administration of avian influenza activities	0.6	
<b>Cumulative Obligations, International Surveillance</b>	<b>88.2</b>	<b>29.7</b>
<b>Unobligated Balances, International Surveillance</b>	<b>0.8</b>	<b>5.3</b>
<b>RAPID RESPONSE</b>	<b>15.0</b>	<b>15.0</b>
CDC Travel and Personnel costs associated with Rapid Response	0.1	0.9
CDC Various contracts and IAAs under \$75,000 each	0.1	0.3
<b>CDC Rapid Response Contracts:</b>		
Bangkok contract for pan flu infrastructure support via cable/containing outbreaks	1.2	0.8
China contract to provide pan flu infrastructure support via cable/containing outbreaks	0.2	0.3
Comforce Technical Services, Inc. contract for international technical, operational services		0.8
Kenya contract to provide pan flu infrastructure support via cable/containing outbreaks	1.8	0.9
McKing Consulting Corp. contract for management consultation		0.4
Northrop Grumman IT, Inc. contract for consulting services		0.2
Total Solutions Inc. contract for support services		0.1
<b>CDC Rapid Response IAAs:</b>		
CID IAA for supplies and materials in Kenya	0.2	
Egypt Embassy IAA for infrastructure support in Egypt	1.2	1.9
U.S. Naval Medical Research Unit No. 2 interagency agreement for the Southeast Asia Influenza Initiative		1.2
Department of State IAA for international cooperative administrative support services		0.2
USAID/Bangkok IAA to provide supplies and materials in Bangkok	0.7	
<b>CDC Rapid Response Grants:</b>		
CDC GAP for NFEC Pacific Division mechanism used to fund and conduct influenza activities	0.5	
China Centers for Disease Control and Prevention grant mechanism used to fund and conduct influenza activities	1.7	
Council of State and Territorial Epidemiology grant for development of state level surveillance systems and training programs		0.1
Department of Medical Sciences grant for special cooperative health investigations and assessments in Thailand	0.5	0.2
International Ctr/Diarrhoeal Disease Research grant for addressing emerging infectious disease in Bangladesh	0.1	0.1
Kenya Medical Research Institute (KEMRI) grant for KEMRI/CDC program	1.9	0.5
National Institute for Communicable Diseases grant for enhancement of surveillance for trimethoprim-sulfamethoxazole resistant inv	0.8	
National Institute for Communicable Diseases grant for South African preparedness for rapid detection of highly pathogenic avian influenza	0.8	0.2
National Institute of Viral Disease Control/Prev grant for support the CDC of The Peoples Republic of China		1.6

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
<b>Pan American Health Organization</b> grant for coordination of comprehensive emerging infectious disease plans		0.8
<b>Thailand Ministry of Public Health</b> grant for prevention and care of infectious diseases	0.8	1.3
<b>Training Programs In Epidemiology</b> grant for China Epidemiology Technical Assistance		0.1
<b>Universidad del valle de Guatemala</b> grant for implementing public health programs and strengthening public health science		1.4
<b>Universidad del valle de Guatemala</b> grant for research and human resource development in human infectious disease in Guatemala	1.9	0.1
<b>USDA Graduate School</b> for training of rapid response personnel		0.1
<b>WHO</b> grant for international staff for special cooperative health investigations, addressing emerging infectious disease and assignments in Thailand	0.6	
<b>Cumulative Obligations, Rapid Response</b>	<b>15.0</b>	<b>14.1</b>
<i>Unobligated Balances, Rapid Response</i>	<i>0.0</i>	<i>0.9</i>
<b>HUMAN ANIMAL INTERFACE</b>	<b>3.0</b>	<b>4.0</b>
CDC Travel and Personnel costs associated with Human Animal Interface	0.2	
<b>CDC Human-Animal Interface Grants:</b>		
<b>Mahidol University</b> grant for avian influenza surveillance in Thailand	0.9	0.9
<b>University of Georgia</b> grant for avian influenza surveillance in the environment	0.2	0.9
<b>University of Minnesota</b> grant for avian influenza cooperative research centers	0.9	0.9
<b>Colorado State University</b> grant for zoonotic avian influenza	0.9	0.9
<b>National Institute of Public Health</b> for Avian Influenza CRC for studies at the human-animal interface		0.2
<b>Cumulative Obligations, Human Animal Interface</b>	<b>3.0</b>	<b>3.7</b>
<i>Unobligated Balances, Human Animal Interface</i>	<i>0.0</i>	<i>0.3</i>
<b>NIH ACTIVITIES</b>	<b>18.0</b>	<b>0.0</b>
<b>Armed Forces Research Institute of Medical Sciences (AFRIMS)</b> contract to conduct studies in Vietnam and China to determine the presence of antibodies against H5N1 in potentially exposed individuals	3.0	
<b>Family Health International and PPD Development</b> contracts for clinical studies support	2.0	
<b>National Center for AIDS Prevention and Control (People's Republic of China)</b> grant to conduct studies in China to investigate H5N1 antibody prevalence and characterize virus from animals and humans in SE Asia	4.0	
<b>Oxford University</b> contract to expand clinical infrastructure and research in SE Asia for therapeutics, diagnostics and vaccines	8.0	
<b>St. Jude's Children's Hospital</b> contract to expand human-animal interface surveillance studies in SE Asia	1.0	
<b>Cumulative Obligations, NIH Activities</b>	<b>18.0</b>	<b>0.0</b>
<i>Unobligated Balances, NIH Activities</i>	<i>0.0</i>	<i>0.0</i>
<b>Cumulative Obligations, International Activities</b>	<b>124.2</b>	<b>47.4</b>
<i>Unobligated Balances, International Activities</i>	<i>0.8</i>	<i>6.6</i>
<b>OTHER DOMESTIC ACTIVITIES FUNDING</b>	<b>138.0</b>	<b>138.0</b>
<b>VACCINE REGISTRY</b>	<b>6.0</b>	<b>10.0</b>
<b>CDC Vaccine Registry Contracts:</b>		
<b>Northrop Grumman Information</b> contract to add pandemic influenza functionality addition to Vaccine Ordering and Distribution System (VODS) to support CDC pandemic planning and operations)	2.2	
<b>CDC Vaccine Registry IAA's:</b>		
IAA to enhance Countermeasure Response Administration (CRA) functionality	3.4	
<b>Cumulative Obligations, Vaccine Registry</b>	<b>5.5</b>	<b>0.0</b>
<i>Unobligated Balances, Vaccine Registry</i>	<i>0.5</i>	<i>10.0</i>
<b>QUARANTINE</b>	<b>20.0</b>	<b>15.9</b>
CDC Travel and Personnel Costs associated with Quarantine	0.9	3.5
CDC Various contracts and IAAs under \$75,000 each	0.5	0.1
<b>CDC Quarantine Contracts:</b>		
<b>Allsteel Inc.</b> contract for Allsteel furniture components including design and installation	0.01	
<b>Cbm/Back LLC</b> contract for back aviation subscription		0.04
<b>Countertrade Products, Inc.</b> contract for networking, computing and IT solutions	0.02	
<b>CounterTrade Products, Inc.</b> contract for Dell servers	0.01	
<b>Crestline Hotels &amp; Resorts</b> contract for hotel rooms		0.01
<b>Dell Marketing L.P.</b> contract for Clin1200 and Optiplex 745 desktop computers		0.01

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Dell Marketing L.P.</b> contract for PowerEdge 6850 servers	0.04	
<b>EC America Inc.</b> contract for CISCO 2811 Integrated Services Routers including power supplies and upgrades	0.04	
<b>Emtec Federal, Inc.</b> contract for computer hardware and software	0.03	
<b>ENV Services Inc.</b> contract for biosafety cabinets	0.1	
<b>Firstwatch Inc.</b> contract surveillance software which is a secure file management and transfer system which analyzes CAD data and automatically conducts surveillance of EMS 911 calls in 24 states and provinces		0.1
<b>Force 3 Inc.</b> contract for CISCO 2811 Integrated Services Routers including, accessories, power supplies and upgrades	0.1	
<b>Hilton Enterprises, Inc.</b> contract for xerox copier		0.01
<b>Insight Public Sector, Inc.</b> contract for software, hardware and equipment	0.1	
<b>IRMH</b> contract to stand up two quarantine stations		0.3
<b>Kimball International, Inc.</b> contract for Kimball Office Furniture		0.01
<b>Knowledge Factor Inc.</b> contract for pan flu learning assessment, creation of core curriculum, and evaluation	0.2	
<b>Lewis Allan Office Furniture</b> contract for array tables	0.1	
<b>Lewis Allan Office Furniture</b> contract for furniture		0.1
<b>Lock Petaluma Mariana Hotel Co. LLC</b> contract for Division of Global Migration and Quarantine (DGMQ) retreat to strategize on preparedness and response activities	0.03	
<b>Lockheed Martin Services Inc.</b> contract for professional and technical support for NCID quarantine activities	0.6	
<b>McKing Consulting Corp.</b> contract to provide management consultation and technical assistance for quarantine	0.1	0.4
<b>McKing Consulting Corporation</b> contract for management consultation and technical assistance, quarantine operational and legal assessment	0.3	0.3
<b>Medstat Group</b> contract for patient claims database	0.04	
<b>Moore Medical LLC</b> contract for Isolation Room Furniture	0.1	
<b>National Associates Inc.</b> contract for media relations specialist	0.1	
<b>National Associates Inc.</b> contract for project manager	0.1	
<b>Northrop Grumman Information Technology Inc.</b> contract for technical support of DHQP pan flu preparedness activities	1.9	0.3
<b>Policy Navigation Group</b> contract for pan flu quarantine policy	0.5	
<b>Professional &amp; Scientific Associates Inc.</b> contract for planning and management of pan flu conference	0.1	
<b>Research Triangle Institute</b> contract to provide services for program policy assessments and evaluation design for quarantine training and education needs	0.8	
<b>Tishman Midwest Management Corp.</b> contract for office space built out of Chicago O'Hare Airport Quarantine Station	0.2	
<b>Trendway Corporation</b> contract for Trendway product		0.04
<b>Trivantis Corporation</b> contract for lectora professional publishing suite	0.03	
<b>Trivantis Corporation</b> contract for publisher	0.01	
<b>CDC Quarantine IAAs:</b>		
<b>COMMERCE/NIST IAA</b> for micro computer support services	0.1	0.1
<b>DGMQ IAA</b> for assessment and evaluation of non-pharmaceutical public health interventions	0.1	
<b>DHHS IAA</b> for a program analyst		0.01
<b>DOE IAA</b> for public healthcare preparedness for DHQP	0.1	
<b>DOE IAA</b> on health care capacity and surge	0.4	
<b>DOE IAA</b> to support table top exercises on pandemic influenza (quarantine system)	0.4	
<b>GSA IAA</b> for multiple hardware and software support items	0.1	
<b>HHS/HRSA &amp; PSC IAA</b> to support quarantine infrastructure at ports of entry for pandemic influenza preparedness		0.7
<b>NCPHI IAA</b> for development of Patient Flu Vaccination Compliance Module & State Health Dept Data Sharing & complete/deploy healthcare personnel safety vaccine module	0.8	
<b>OPM IAA</b> for expansion of infection control capacity (nat'l response & training)	0.6	
<b>OPM IAA</b> for reimbursement fee for PMF program for pandemic-related staff	0.01	0.01
<b>OPM IAA</b> to support pandemic influenza simulation project	0.2	
<b>ORISE IAA</b> for tabletop exercises for healthcare preparedness	0.3	
<b>SAMHSA IAA</b> to purchase adverse drug event data from SAMHSA	0.1	
<b>Teresa Hope IAA</b> for technical assistance and health communications research		0.2
<b>VA IAA</b> for global mapping and migration project		0.1
<b>CDC Quarantine Grants:</b>		
<b>ASTHO</b> grant for nursing and Epidemiologist Cooperative Agreement to Enhance BioSurveillance Capabilities	1.0	
<b>Boston Medical Center</b> grant for Boston Area Travel Medicine Network (Batmn)		0.4

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
<b>Boston Medical Center</b> grant for Boston Area Travel Medicine Network (Batmn)		0.2
<b>Commonwealth N. Marianas Islands Dept. of Public Health</b> grant used to fund regional reference laboratories for communicable and outbreak prone diseases including influenza		0.04
<b>DGMQ-QBHSB</b> grant to support and train quarantine system personnel for pandemic readiness	0.2	
<b>Emory University</b> grant for cooperative agreement for pan flu assistance: Biostatistician		0.1
<b>Emory University</b> grant for cooperative agreement for special projects of national significance	0.1	
<b>Hawaii Department of Health</b> grant for epidemiology and lab capacity for infectious diseases		0.3
<b>International Rescue Committee</b> grant for improving detection, surveillance, and response for influenza in immigrants and refugees	0.3	0.3
<b>International Society of Tropical Medicine</b> grant for global surveillance network to detect influenza among travelers and other outbreaks of public health significance	0.3	0.3
<b>Johns Hopkins University</b> grant for analysis of legal implications of quarantine during pandemic influenza (state, local, and federal authorities)	0.03	
<b>Kenya Medical Research Institute (KEMRI)</b> grant for KEMRI/CDC program		0.1
<b>Massachusetts General Hospital</b> grant for Global Travelers' Health National Research Center Consortium		0.8
<b>Regents of the University of California</b> grant for effectiveness of selected non-pharmaceutical interventions in reducing influenza like illness among students	0.5	0.5
<b>Regents of the University of Michigan</b> contract for quarantine flu research	0.8	
<b>Regents of the University of Michigan</b> contract for study and reports		0.8
<b>Regents of the University of Michigan</b> grant for reducing transmission of influenza by face masks	1.1	1.1
<b>Regents of the University of Minnesota</b> grant for early detection, surveillance, and response for highly pathogenic influenza A viruses	0.5	
<b>Research Triangle Institute</b> grant for non-pharmaceutical interventions for pandemic influenza	0.8	0.7
<b>SMRU-faculty of Tropical Medicine</b> grant for avian flu surveillance network in displaced populations on the Thai Burma border	0.3	0.2
<b>The Medstat Group</b> grant for patient claims database	0.1	
	1.1	0.9
<b>Trustees of Columbia University</b> grant for stopping upper respiratory infections and flu in the family trial		
<b>University of Hong Kong</b> grant for a Controlled Trial of Masks and Hand Hygiene For Reducing Influenza Transmission		0.02
<b>University of Hong Kong</b> grant for cooperative agreement for pandemic influenza assistance	0.3	1.0
<b>University of Massachusetts-Lowell</b> grant for evaluation of masks as a source control NPI (non-pharmaceutical intervention)	0.3	0.3
<b>University of Otago</b> grant for pandemic influenza control at the borders of island countries and in household		0.5
<b>University of Otago</b> grant for pandemic influenza control at the borders of island countries and in households	0.4	
<b>University of Pittsburgh</b> grant for Pittsburgh influenza prevention project	0.8	0.8
<b>Wake Forest</b> cooperative agreement for aerobiology study of mask and respirator efficacy to prevent respiratory viral infection in a human model	0.7	
<b>World Health Organization</b> grant for special cooperative health investigations and assessments	0.1	
<b>Cumulative Obligations, Quarantine</b>	<b>19.5</b>	<b>15.8</b>
<b>Unobligated Balances, Quarantine</b>	<b>0.5</b>	<b>0.1</b>
<b>LAB CAPACITY</b>	<b>50.0</b>	<b>30.0</b>
CDC Travel and Personnel Costs associated with Lab Capacity	10.4	2.7
CDC Various Contracts and IAAs Under \$75,000 Each	2.0	0.4
<b>CDC Lab Capacity IAAs:</b>		
<b>America's Health Insurance Plans</b> IAA for development of an influenza bio-bank in a managed care setting	1.0	
<b>Atlanta Veterans Affairs Medical Center</b> IAA for improved diagnostics for viral causes of infectious disease	2.0	
<b>Department of Health &amp; Human Services</b> for research participation program in Ncpdcid/Dsr/Bb		0.1
<b>Department of Health &amp; Human Services</b> for research participation program in Ncpdcid/Dsr/Od		0.04
<b>DOC</b> for microcomputer support services	0.1	
<b>DOD's Chemical and Biological Defense Information Analysis Center (CBIAC)</b> award to engage CBIAC resources in research by providing scientific and technical services to DLS	0.5	
<b>DOE</b> for development of methods for pox virus diagnostic and characterization		0.1
<b>DOE</b> for research participation program	0.1	0.1
<b>DOS</b> for capital security cost sharing programs	0.03	
<b>Fedsorce</b> for Administrative Assistant	0.1	

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Fedsource</b> for Support for the Office of the Director, DVRD	0.2	
<b>FMO</b> for ICASS	0.02	
<b>GSA Rand</b> IAA to provide tools to identify and address challenges at the national and regional levels related to planning, surveillance and response to public health emergencies	0.5	
<b>Indian Health Service</b> IAA for preventing infectious disease among residents of Arctic and Sub-Arctic	0.1	
<b>Los Alamos National Lab</b> for Influenza viral sequence database	0.3	
<b>OPM</b> IAA for support services through Booz-Allen-Hamilton	0.5	
<b>ORISE</b> IAA to design, coordinate, conduct and report on a series of meetings for regional public health-healthcare personnel to focus on issues of surge capacity relative to pandemic influenza response	0.2	
<b>PHS</b> for writer/editor for hazard evaluations and technical assistance branch		0.1
<b>USAID</b> IAA to enhance international efforts for wild bird surveillance for avian influenza	1.0	
<b>USAID</b> to systematically document and disseminate information about the National health care services infrastructure	0.1	
<b>CDC Lab Capacity Grants:</b>		
<b>American Society of Law Methods &amp; Ethics</b> grant to build system capacity to apply law as a public health tool	0.1	
<b>Association of Public Health Laboratories</b> for national laboratory training and management information systems	0.8	
<b>CARE</b> for technical support of pan flu preparedness activities	0.4	
<b>CDC DGMQ-QBHSB</b> to support and train quarantine system personnel for pandemic readiness	2.1	
<b>Direct Gen/Disease Control Jakarta</b> for surveillance and response to avian and pandemic influenza	0.1	
<b>International Rescue Committee</b> cooperative agreement used as mechanism to build capacity in Indonesia	0.1	
<b>Iowa State University</b> for pathogenesis of infections in swine with pathogenic avian influenza virus	0.4	
<b>Marshall Clinic Research Foundation</b> for rapid analysis of influenza vaccine effectiveness	0.5	
<b>Mount Sinai</b> for Development of guinea pig as mammalian model for influenza virus transmission	0.3	
<b>National Institute of Public Health &amp; Environment, Netherlands</b> for avian influenza CRC studies at the human-animal interface	0.3	
<b>Oregon State University</b> for replication of highly pathogenic avian influenza viruses in swine	0.2	
<b>University of Georgia</b> for probability of human contact with avian influenza viruses in the environment	0.7	
<b>University of Maryland</b> for mechanisms of influenza A virus transmission in ferrets	0.2	
<b>Vietnam Veterans of America Foundation</b> used as mechanism to build capacity in Indonesia	0.5	
<b>CDC Lab Capacity Contracts:</b>		
<b>A. Daigger &amp; Company, Inc.</b> for Frezer Upright, Gel System, Power Supply, Pipet-Aid Portable, Spectrafuge Mini, Explosion, Analytical 210Gx. 1Mg, Isotmp + Ref, Vortex Geie 2, Toploader Mettler, Ceramic Strihotplate	0.1	
<b>AFFYMETRIX Inc.</b> contract for work station	0.2	
<b>Agilent Technologies, Inc.</b> for bioanalyzer laptop system	0.03	
<b>Agilent Technologies, Inc.</b> for Capillary Pump, Capillary Kit, 1200 Micro Well-Plate Sampler, Thermostat For Als/Fc/Spotter, 1200 Thermostatted Column Compartme, 1200 Series Instant Pilot Control M, 1200 External Contacts, 1200 Binary Pump, 1200 Fraction Collector, 1200 Thermostatted	0.1	
<b>America's Health Insurance Plans</b> contract to provide Office of Genomics and Disease Prevention (OGDP) with vaccine safety services	1.2	
<b>Amersham Biosciences</b> contract for lab equipment	0.2	
<b>Applera Corp.</b> contract for 96 cap DNA analyzer	0.3	
<b>Applera Corp.</b> contract for Applied Biosystems 7500 Real-Time PCR System	0.1	
<b>Applera Corp.</b> contract for array upgrade kit	0.2	
<b>Applera Corp.</b> Contract for ABI PRISM® 3100 Genetic Analyzer to Applied Biosystems 3130xl System Upgrade with computer	0.03	
<b>Applera Corp.</b> contract for spectrometer package, discovery system, and accessories	0.7	
<b>Applied Biosystems</b> contract for QST, 7500 fast realtime, tower, computer equipment	0.1	
<b>Applied Maths, Inc.</b> for bionumerics module V4.6 sequencing software required for DNA sequence data analysis and DNA fragment analysis		0.03
<b>Batelle Memorial Institute</b> contract to supporty the project "Reaerosolization of Viruses from NIOSH-certified Filtering Facepiece Respirators"	0.1	
<b>Bc Group, LLC</b> for display system	0.1	
<b>Bearingpoint, LLC</b> for technical support	0.1	
<b>Beckman Coulter Inc.</b> for Vi cell system equipment	0.1	
<b>Beckman Coulter, Inc.</b> for optima max ultracentrifuge	0.0	
<b>Becton, Dickinson and Company</b> for Bd Facscanto Ii Flow Cytometer Ivd	0.1	
<b>Beta South Technology Inc.</b> for Cyler System Ii and Smart System	0.1	



<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
Beta South Technology Inc. for cycler system II and smart system	0.1	
Biacore Inc. contract for BIOCORE T-100 unit	0.3	
Biaera Technologies contract for PLA001a and other lab equipment	0.1	
Biaera Technologies Inc. for AEROmp automation interface module	0.1	
Biomedic Data Systems Inc. for Das 6007 scanner system	0.03	
Biomerieux Vitek, Inc. for easy mag extraction system	0.1	
Biomicro Systems Inc. for Maui 12 Bay Hybridization System	0.04	
Bio-Rad Laboratories, Inc. for freight	0.1	
Bio-Rad Laboratories, Inc. for mini opticon	0.02	
Bioteam, Inc. for Bioteam Inquiry	0.02	
BL Seamon Corp. contract to coordinate and manage 2007 summit meeting for emergency legal preparedness and public health	0.1	
Booz Allen Hamilton Inc. contract to provide evaluation of pandemic influenza operational plan	0.3	
Carl Zeiss Microimaging Inc. contract for microimaging equipment	0.3	
Cellular Technology Ltd for Ctl-Immunospot S5 microanalyzer	0.1	
Chickasaw Advisory Services LLC for pandemic influenza project, Task E	0.03	
Cni Construction, LLC for supplies/services	0.03	
Columbus Instruments International Corp. for microcapnograph model 240	0.02	
Computer Sciences Corporation contract for worksite health promotion	0.2	
Consolidated Safety Services Inc. contract for bio-safety training for Federal employees	0.1	
Countertrade Products, Inc. contract for networking, computing and IT solutions	0.1	
Dataworks Development Inc. for Freezerworks Unlimited 2.0 software	0.02	
Dataworks Development Inc. for software network	0.02	
Db Consulting Group, Inc. for management consultation and technical support		0.1
Dell Marketing L.P. for 690 mini tower		0.02
Direct Dimensions, Inc. for 3-day custom training, polyworks software upgrade	0.04	
Drew Scientific, Inc. for analyzer	0.02	
Eaton Power Quality Corp. for uninterruptible power system	0.03	
EG&G Technical Services contract for scientific, professional and engineering support services for the National Personal Protective Technology Laboratory	0.7	0.1
Eksigent Technologies LLC contract for system, nano LC-2D HPLC and warranty	0.3	
Eksigent Technologies, LLC for Hplc system	0.1	
Environmental Systems Research Institute Inc. for license		0.03
Eppendorf North American, Inc. for Eppendorf centrifuge	0.1	
UNICOR Federal Prison Industries, Inc. for 150 Black Fabric Chairs	0.1	
Fisher Scientific Company LLC for hazardous materials	0.1	
Global Technology Solutions contract for sunrack	0.2	
Goldbelt Raven Inc. contract for 171-000205 Bioplex 200	0.1	
Goldbelt Raven Inc. contract for bioanalyzer laptop system	0.03	
Goldbelt Raven Inc. contract for general purpose fisher undercounter	0.02	
Goldbelt Raven Inc. contract for i-cycler thermal cycler-96-well and Versadoc 5000 system	0.2	
Goldbelt Raven Inc. contract for Mj DNA engine	0.1	
Goldbelt Raven LLC contract for MJ Tetrad thermal cycler and alpha engine	0.1	
Goldbelt Raven LLC contract for MX 3005P QPCR system and service	0.1	
Goldbelt Raven LLC contract for Qiagen biorobot, equipment and installation	0.2	
Government Scientific Source Inc. contract for Elx405 microplate washer	0.02	
Government Scientific Source Inc. contract for gene pix scanner and desktop	0.1	
	0.1	
Government Scientific Source Inc. contract for M5 instrument w/ softmax pro, lap top bundle, agreement		
Government Scientific Source Inc. contract for Sakura Tissue Tek Auto TEC embedding	0.2	
Immix Technology Inc. for 300 GB, 120k RPM, Universal FC disk, appliance and software	0.1	
Johnson Controls Inc. for C118 vivarium readers	0.04	
Johnson Controls Inc. for Sa freezer lock	0.02	
JSJ and Associates for technical services		0.03
Klarquist Sparkman, LLP contract for technical services, option period 4	0.02	
Krackeler Scientific Inc. for air driven ultracentrifuge	0.02	
Krug Inc. contract for office furniture and equipment	0.1	
Lewis Allan Office Furniture contract for components	0.1	
Lewis Allan Office Furniture contract for office furniture and installation	0.1	
Lewis Allan Office Furniture contract for technical assistance, consulting, supplies, and equipment supporting laboratory capacity activities	0.04	

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Lockheed Martin</b> contract for Consultation Service, Facilitation Services, Project Management and Technical Support to the National Center for Infectious Diseases (NCID)		0.5
<b>Lockheed Martin</b> contract for COTPER DEOC staffing		0.2
<b>Lockheed Martin</b> contract for DSNS staffing		0.2
<b>Lyme Computer Systems Inc.</b> contract for mat lab for hi-throughput lab	0.1	
<b>Matrix Science Ltd</b> contract for mascot server, workstation, search toolbox, mascot toolbox	0.1	
<b>McKing Consulting Corp.</b> contract for management consultation and technical assistance	1.7	
<b>McKing Consulting Corp.</b> contract to provide Office of Genomics and Disease Prevention (OGDP) with management consultation and technical assistance	0.04	
<b>MPRI, Inc.</b> contract to draft pandemic operational plan and provide operational support	6.6	3.5
<b>Nanodrop Technologies Inc.</b> contract for spectrophotometer	0.04	
<b>National Academy of Sciences</b> contract to provide research associates for the National Personnel Protective Laboratory (NPPTL)	0.1	
<b>National Associates Inc.</b> contract for public affairs specialist	0.1	
<b>Northrop Grumman</b> contract to develop and support the StarLIMS Laboratory Information Management Systems services	0.3	2.2
<b>Northrop Grumman Information Technology</b> contract for technical support of pan flu preparedness activities	0.2	
<b>Nuaire, Inc.</b> contract for silicone sleeve connection kit, manual butterfly, thimble exhaust transition, tables and shipping	0.1	
<b>Office Speciality Ltd.</b> Contract for 366-66-Lu5F10	0.04	
<b>Professional &amp; Scientific Associates Inc.</b> contract for international travel and logistical support services	0.1	
<b>Progroup Instrument Inc.</b> contract for Well Pro Liquid Handler	0.1	
<b>Progroup Instrument Inc.</b> contract for Well Pro WP 3000	0.1	
<b>Protein Sciences Corporation</b> contract for H7N2	0.02	
<b>Qiagen Inc.</b> contact for biorobot Ez1 workstation, for automated purification of nucleic acids from 1-6 clinical or forensic samples	0.1	
<b>Roche Diagnostics Corp.</b> contract for genome sequencer 20 instrument	0.2	
<b>Roche Diagnostics Corp.</b> contract for instrument	0.03	
<b>Roche Diagnostics Corp.</b> contract for magna pure	0.1	
<b>Roche Diagnostics Corp.</b> contract for magna pure compact	0.03	
<b>Roche Diagnostics Corp.</b> contract for MagNaPure LC with light cyclers	0.2	
<b>Sanyo Commercial Solutions</b> contract for biomedical and lab refrigerators and freezers	0.02	
<b>Sartorius Bbi Systems Inc.</b> contract for biostat Ct	0.1	
<b>Sartorius Corporation</b> contract for Sartoclon Slice Benchtop System with 3.1L Tank (The Sartoclon Slice Benchtop is a basic cost effective Crossflow filtration system for small Micro and Ultrafiltration applications.)	0.02	
<b>Society for Public Health Education</b> contract for Hhp Supplement	0.1	
	0.2	1.2
<b>STARLIMS Corp.</b> contract for StarLIMS Enterprise Development Kit, Implementation Services and Entries		
<b>The Scripps Research Inst.</b> Contract for influenza binding assays	0.4	
<b>Thermo Electron Corp.</b> contract for LTQ ORBITRAP/ESI bundle	0.5	
<b>Thermo Electron Corp.</b> contract for LTQ ORBITRAP/ESI bundle	0.6	
<b>Thermo Electron Corp.</b> contract for mezzanine, single large shelf	0.03	
<b>Thermo Fisher Scientific (Asheville) LLC</b> contract for 75004377	0.1	
<b>Thermo Forma Inc.</b> contract for Model 8607	0.04	
<b>Tkc Integration Services LLC</b> contract for Spectra T50	0.02	
<b>Tsi Incorporated</b> contract for 3321 aerodynamic particle sizer	0.04	
<b>University of Virginia</b> contract for pediatric serum survey	0.03	
<b>Vashaw Scientific Inc.</b> contract for 14.9Cv.Ts5.025	0.1	
<b>Waters Corp.</b> contract for MS system, software and equipment	0.6	
<b>Waters Corp.</b> contract for solvent mgr. warranty, sample mgr. warranty, acquity uplc	0.1	
<b>Westwood Computer Corp.</b> contract for computer equipment	0.2	
<b>Xenogen</b> contract for IVIS SYSTEM 120V	0.3	
<b>Cumulative Obligations, Lab Capacity</b>	<b>48.5</b>	<b>11.5</b>
<b>Unobligated Balances, Lab Capacity</b>	<b>1.5</b>	<b>18.5</b>
<b>BIONSENSE</b>	<b>35.0</b>	<b>0.0</b>
CDC Travel & Personnel Costs associated with Biosense	1.2	
CDC Various contracts and IAAs under \$75,000 each	0.4	
<b>CDC Biosense Contracts:</b>		
<b>America's Health Insurance Plans</b> AREF for improved diagnostics for viral causes of infectious diseases	2.1	

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Atlanta Veteran's Affairs Medical Center</b> for epidemiologic data manager	0.2	
<b>Biosense Support Cable</b> for Global Disease Detection in China	0.1	
<b>Datallne Inc.</b> contract for data hardware and software for DISS biosense infrastructure	1.5	
<b>Lockheed Martin Services Inc.</b> contract for technical support of pan flu preparedness activities	0.5	
<b>McKing Consulting Corp.</b> contract for DEPR Management Consultation for Biosense Infrastructure Support	0.3	
<b>Northrop Grumman Information Technology</b> contract for technical support of pan flu preparedness activities	2.9	
<b>STARLIMS Corp.</b> contract for StarLIMS Enterprise Development Kit and Implementation services	0.4	
<b>Total Solutions Inc.</b> contract for technical support of pan flu preparedness activities	0.1	
<b>Unisys Corp.</b> contract for equipment and supplies for DEPR Biosense Infrastructure Support	1.1	
<b>Unisys Corp.</b> contract for Technical assistance for DISS Biosense Infrastructure Support	0.5	
<b>CDC Biosense IAA's:</b>		
<b>FEDSOURCE</b> IAA for technical assistance to infectious disease pathology	0.1	
<b>Constella</b> IAA for Recruitment and Implementation of Data Sources for BioSense Application	4.9	
<b>DEPR Healthcare</b> IAA for IT Standard Integration	0.4	
<b>Gartner</b> IAA for Independent Verification Validation of the BioSense Program	1.6	
<b>GSA - Northrup and CSC</b> IAA to develop and Support Decision System Specific to Influenza for use in the BioSense Application-Federal Information Systems Support (FISSP)	0.4	
<b>GSA</b> IAA to build and support the Secure Data Network	0.6	
<b>GSA</b> IAA to develop and Support Decision System Specific to Influenza for use in the BioSense Application-Enterprise Information and Technical Infrastructure Technical Services (EITITS)	1.6	
<b>GSA</b> IAA To Fund the Epidemiology Career Training Program (ECTP)	0.4	
<b>National Retail Data Monitoring (NRDM)</b> IAA to Access BioSurveillance Relevant Information from Over the Counter Retail Data Sources	0.5	
<b>Per Se</b> IAA to access biosurveillance relevant information for pharmaceutical data sources	0.6	
<b>CDC Biosense Grants:</b>		
<b>Association of American Medical Colleges</b> grant for program improvements for schools of public health	0.1	
<b>Association of Public Health Laboratories</b> grant for National Laboratory Training Network and Management Information Systems	1.8	
<b>Association of Schools of Public Health, Inc.</b> grant for the improvement of interaction between PHAS and PHPS	0.1	
<b>ASTHO</b> grant for Nursing and Epidemiologist Cooperative Agreement to Enhance BioSurveillance Capabilities	0.7	
<b>International Society of Disease Surveillance (ISDS)</b> grant to Enhance the Capacities of Disease Surveillance	0.6	
<b>NAPHSIS Foundation Inc.</b> grant for vital statistics re-engineering program	0.7	
<b>CDC Biosense Grants for population-based domestic surveillance:</b>		
<b>California</b>	0.1	
<b>Colorado</b>	0.1	
<b>Connecticut</b>	0.1	
<b>Georgia</b>	0.1	
<b>Maryland</b>	0.1	
<b>Minnesota</b>	0.3	
<b>New Mexico</b>	0.1	
<b>New York</b>	0.2	
<b>Oregon</b>	0.1	
<b>Tennessee</b>	0.1	
<b>CDC Biosense Grants for population-based surveillance for influenza among children:</b>		
<b>Cincinnati Children's Hospital</b>	0.3	
<b>University of Rochester</b>	0.3	
<b>Vanderbilt University</b>	0.3	
<b>Cumulative Obligations, Biosense</b>	<b>28.2</b>	<b>0.0</b>
<b>Unobligated Balances, Biosense</b>	<b>6.8</b>	<b>0.0</b>
<b>RAPID TESTS FUNDING</b>	<b>27.0</b>	<b>40.0</b>
CDC Travel and Personnel Costs associated with Rapid Tests	1.5	
CDC Various contracts and IAAs under \$75,000 each	0.5	
<b>CDC Rapid Tests Contracts:</b>		
<b>A. Daigger And Company, Inc.</b> contract for combi refrigfreezer 2 door 115V	0.01	
<b>Agilent Technologies, Inc.</b> contract for 2100 Bioanalyzer	0.02	

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
APHL contract for National Laboratory Training Network & Management Information Systems	0.9	
Applera Corporation contract for 7500 fast real time PCR	0.04	
Applied Biosystems contract for Tf Bdt V.3.1 Rx-1000 Seq. Buffer	0.02	
Applied Biosystems contract for Tf, Na-Star Influenza Nird Kit	0.02	
Beckman Coulter, Inc. contract for Msa for Beckman Fx	0.02	
Cepheid contract for advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	2.4	
Corbett Robotics Inc. contract for 650H-300	0.04	
Eppendorf North America, Inc. contract for Epmotion 5075 Lh Pc-Control Comp	0.1	
GE Healthcare Bioscience Bioprocess Corp. contract for Exosap-It (2000 Rxn)	0.01	
Goldbelt Raven LLC contract for Stratagen Mx 3005 Real-Time Pcr Mac	0.1	
Government Scientific Source contract for hardware and software	0.2	
Government Scientific Source Inc. contract for Cas-1200 Pcr Liq Handling Sys	0.1	
Intermountain Scientific Corporation contract for capless microcentrifuge tubes 1.7 mL	0.01	
Iquum LLC contract for advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	3.8	
Medical Staffing Network, Inc. contract for lab workers	0.2	
Meso Scales Diagnostic LLC contract for advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	0.7	1.3
Midwest Research Institute, Inc. contract for quarterly report	0.2	
Nanodrop Technologies, Inc. contract for Nd-1000 spectrophotometer	0.01	
Nanogen Inc. contract for advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	4.5	
Northrop Grumman Information Technology, Inc. contract for technical support of rapid testing activities	0.4	
Promega Corporation contract for bench top pgem DNA markers	0.02	
Qiagen Inc. contract for Magattract Viral RNA M48	0.01	
Rainin Instrument, LLC contract for Edp+3 Elec Lts 88-Ch Pipet 0.5-10U1	0.01	
Roche Diagnostics Corporation contract for Lightcycler 1.5 System+Laptop	0.02	
Thermo Fisher Scientific (Ashville) LLC contract for Forma Ultra Low - 900 Series Upright	0.01	
Thermo Fisher Scientific (Ashville) LLC contract for Ult Frzr 17 U.R.DblDr 120	0.01	
Unisys Corporation contract for prove portfolio management support	0.4	
Utech Products Inc. contract to Synergy 2 Multi-Detection Microplat	0.02	
Zeptomatrix Corporation contract to establish repository	0.8	
Zeptomatrix Corporation to provide unique and quality assured influenza-related reagents and resources in support of accelerated development of clinical diagnostic products for human influenza	1.5	
<b>CDC Rapid Tests Grants:</b>		
Marshfield Clinic Research Foundation grant for a trial to determine antiviral effectiveness and to obtain respiratory specimens from study patients to be used for diagnostic test evaluation	2.8	
<b>CDC Rapid Tests IAA's:</b>		
DOD IAA for HHS/CDC Influenza Diagnostics Enhancement Research and Development	2.3	
OPM IAA for pandemic influenza capacity management support	0.3	
VA IAA for purchase of antiviral drugs to be used for prophylaxis of CDC personnel to ensure sustainability of CDC's capability to do rapid testing to confirm influenza diagnoses and genotype influenza virus isolate during a pandemic	0.04	
<b>Cumulative Obligations, Rapid Tests</b>	<b>23.8</b>	<b>1.3</b>
<b>Unobligated Balances, Rapid Tests</b>	<b>3.2</b>	<b>38.7</b>
<b>LIBRARY OF REFERENCE STRAINS FUNDING</b>		
	<b>0.0</b>	<b>12.1</b>
CDC Travel and Personnel Costs associated with Library of Reference Strains		2.2
CDC Various contracts and IAAs under \$75,000 each		1.8
<b>CDC Library of Reference Strains Contracts:</b>		
A. Daigger And Company, Inc. contract for microcentrifuge with rotor		0.01
Affymetrix Inc. contract for geno chip human genome		0.02
Affymetrix Inc. contract for Hyb Oven And Fs450		0.1
Amata, Inc. contract for Aad-1001S Nucleofector Ii Device		0.01
Amata, Inc. contract for Nucleofector Ii Device		0.01
Applera Corporation contract for primer express license		0.01
Becton, Dickinson And Company contract for Bd Lsr Ii 3-Laser System		0.4
Benchmark Biolabs, Inc. Clinical Safety and Challenge Study		0.1
Biaera Technologies LLC contract for Cha004 Custom Rodent Inhalation Challenge		0.03
Biodiscovery, Inc. contract for Array Image Analysis Software		0.01

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Biorellance Corp.</b> contract for production of master and working banks of mammalian cell lines under cGMP conditions		0.1
<b>Bio-Tek Instruments</b> , contract for Elx405Vrs		0.04
<b>Bio-Tek Instruments</b> , contract for Elx405Vrs microplate washer		0.03
<b>Carl Zeiss Microimaging Inc.</b> contract for Axio Observer A1 12V/100W Kit		0.1
<b>Carl Zeiss Microimaging Inc.</b> contract for Axio Observer Z1 Motorized Microscope		0.1
<b>Carl Zeiss Microimaging Inc.</b> contract for Axioimager Microscope		0.03
<b>Charles River Laboratories, Inc.</b> contract for four strains of female mice		0.1
<b>Dell Marketing L.P.</b> contract for 745 Minitower		0.01
<b>Dell Marketing L.P.</b> contract for Clin 1300, Optiplex 745 Minitower		0.01
<b>Dell Marketing L.P.</b> contract for Intel Core2 Extreme Processors		0.02
<b>Dell Marketing L.P.</b> contract for laptop		0.00
<b>Dell Marketing L.P.</b> contract for Optiplex 745 Minitower		0.02
<b>Dell Marketing L.P.</b> contract for Pvt Lto-4 Tape Drive		0.01
<b>Emory University</b> contract for sialoglycan beads		0.2
<b>Emtec Federal, Inc.</b> contract for computer equipment and monitors		0.01
<b>Excel Technologies, Inc.</b> contract for Ts100-F W/Trinoc Iso		0.01
<b>Fluidigm Corporation</b> contract for Tpz-Fid Fid Crystallizer System		0.2
<b>GE Healthcare Bioscience Bioprocess Corp.</b> contract for Decyder V 6.5 Add 1 User License		0.0
<b>GE Healthcare Bioscience Bioprocess Corp.</b> contract for Flow Cell Air-925		0.1
<b>Government Scientific Source Inc.</b> contract for 77888-200 Centrifuge 5415D		0.1
<b>Government Scientific Source Inc.</b> contract for Cfa01M2230-03		0.01
<b>Infotech Biosystems International</b> contract for Im-250 2.5Mm Strip Cutter		0.01
<b>Kemp Biotechnologies Inc.</b> contract for 20 Mg of Recombinant IgG For H5 HA		0.01
<b>Krackeler Scientific Inc.</b> contract for Centrifuge, Thermo Iec		0.01
<b>Lab Products Inc.</b> contract for Bioclean		0.01
<b>LSO-Low Environmental Equipment Co Inc.</b> contract for Lab Refrigerator With Chart Rec/Ala		0.01
<b>Luminex Corporation</b> contract for Luminex Software upgrade kit		0.01
<b>Marcon International (USA)</b> contract for Vwr Freezer, Up 23 Cuft -86		0.1
<b>Mcking Consulting Corporation</b> contract for management consultation		0.03
<b>New Brunswick Scientific Co., Inc.</b> contract for Innova Model 4230 Refrigerated Stac		0.02
<b>New Brunswick Scientific Co., Inc.</b> contract for Innove Model 44R Refrigerated Incub		0.1
<b>Nexcelom Bioscience LLC</b> contract for Cellometer T4 System		0.01
<b>Professional &amp; Scientific Associates Inc.</b> contract for international travel and logistical support		0.01
<b>Progroup Instrument Inc</b> contract for Well Pro Wp3000 Liquid Handler		0.02
<b>Qiagen Inc.</b> contract for Biorobot M48		0.1
<b>Rainin Instrument, LLC</b> contract for Pipet-Lite Lts Magnetic Assist Pipe		0.02
<b>Roche Diagnostics Corporation</b> contract for magna lyser		0.01
<b>Sanyo Commercial Solutions</b> contract for -150C Cryogenic Freezer		0.02
<b>Specialty Gases Southeast, Inc.</b> contract for freezer		0.01
<b>Synoptics Inc.</b> contract for 05-Gbox-Hr		0.01
<b>The Scripps Research Institute</b> contract to provide draft of written protocol		0.3
<b>Thermo Fisher Scientific (Ashville) LLC</b> contract for Hera Cell Co2Incubator		0.01
<b>Thermo Fisher Scientific (Ashville) LLC</b> contract for Slc-4000 Fixed Angel Composite Roto		0.01
<b>Thermo Forma Inc.</b> contract for lab equipment		0.2
<b>Triple F Farms Inc.</b> contract Ferrets - Influenza A And B Viruses		0.2
<b>VWR International, Inc.</b> contract for Animal Sera, Hyclone		0.01
<b>Cumulative Obligations, Library of Reference Strains</b>	<b>0.0</b>	<b>7.1</b>
<i>Unobligated Balances, Library of Reference Strains</i>	<i>0.0</i>	<i>5.0</i>
<b>DIAGNOSTIC REAGENT STOCKPILE FUNDING</b>	<b>0.0</b>	<b>13.0</b>
CDC Travel and Personnel Costs associated with Diagnostic Reagent Stockpile		1.3
CDC Various contracts and IAAs under \$75,000 each		0.6
<b>CDC Diagnostic Reagent Stockpile Contracts:</b>		
<b>Accurate Chemical &amp; Scientific</b> contract for YCC34012 Receptor Destroying Enzyme		0.02
<b>Applera Corporation</b> contract for Na-Star Influenza Nird Kit		0.1
<b>Applied Biosystems</b> contract for Na-Star Influenza Nird Kit		0.2
<b>Biosearch Technologies</b> contract for dual-labeled probe		0.02
<b>Biosearch Technologies</b> contract for Influenza Primer/Probe Kits		0.2
<b>Caliper Life Sciences, Inc.</b> contract for Ht Dna 12K Labchip Kit		0.01
<b>Caliper Life Sciences, Inc.</b> contract for Labchip 90 Automated Priming Statio		0.01
<b>Carl Zeiss Microimaging Inc.</b> contract for Axiovert 40 C Stand		0.03
<b>Dell Marketing L.P.</b> contract for Optiplex 745 Minitower		0.01

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Fisher Scientific Company LLC contract for Shaker, Incub, Excella E-24		0.01
Goldbelt Raven LLC contract for Rotor-Gene 6000		0.04
Government Scientific Source Inc. contract for Ptc0240 Tetrad2 Chassis		0.03
Invitrogen Corporation contract for Superscript Iii Platinum One-Step R		0.02
J L S Research contract for 201 To 400 Dozen Per Week		0.1
Kuhl Corp. contract for Azys960-110 W/Cm 48 Trays		0.01
Lab Depot, Inc. contract for Code Reader 3 Scanner		0.02
Lectinity Holdings, Inc. contract for New5Ac Fluoregenic Substrate (5 Gra		0.02
Mason Box Company contract for World Health Organization boxes		0.01
Nanodrop Technologies, Inc contract for 8 Sample Spectrophotometer-Nanodrop		0.02
Perkinelmer Las, Inc. contract for Victor V With 5-Techs		0.1
Professional & Scientific Associates Inc. contract for international travel & logistical support services		0.03
Progroup Instrument Inc. contract for Wellpro Wp3000 Liquid Handler		0.02
Sigma-Aldrich Corporation contract for P/N M8639-Conf		0.01
The Mathworks Inc. contract for Matlab Distrib Computing Engine 16P		0.02
The Mathworks Inc. contract for P2187 Biotech Advisory Services		0.02
Thermo Fisher Scientific (Ashville) LLC contract for Thermo Model 8606 -86C Upright Freezer		0.01
Virginia Commonwealth University contract for serum survey funding		0.03
<b>CDC Diagnostic Reagent Stockpile Grants:</b>		
WHO grant for addressing emerging infectious diseases		0.5
<b>CDC Diagnostic Reagent Stockpile IAA's:</b>		
GSA IAA for Rent		0.9
<b>Cumulative Obligations, Diagnostic Reagent Stockpile</b>	<b>0.0</b>	<b>4.3</b>
<i>Unobligated Balances, Diagnostic Reagent Stockpile</i>	<i>0.0</i>	<i>8.7</i>
<b>REAL-TIME ASSESSMENT FUNDING</b>	<b>0.0</b>	<b>7.0</b>
<b>CDC Real-Time Assessment IAA's:</b>		
GSA IAA for March rental bill		0.1
<b>CDC Real-Time Assessment Contracts:</b>		
Goolsby, Kimberly contract for recorder services		0.01
<b>CDC Real-Time Assessment Grants for epidemiology and laboratory capacity for infectious diseases:</b>		
Alabama		0.02
Alaska		0.1
Arizona		0.1
Arkansas		0.1
Chicago		0.1
Colorado		0.1
Connecticut		0.1
Council of State & Territorial Epidemiologists		0.3
Delaware		0.1
District of Columbia		0.1
Florida		0.1
Georgia		0.1
Hawaii		0.2
Health Research Inc./NYC Dept. of Health		0.2
Houston		0.1
Idaho		0.1
Illinois		0.1
Indiana		0.1
Iowa		0.2
Kansas		0.01
Kentucky		0.1
Louisiana		0.1
Maine		0.1
Massachusetts		0.1
Michigan		0.2
Minnesota		0.1
Mississippi		0.1
Missouri		0.1
Montana		0.1
Nebraska		0.1

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Nevada		0.1
New Hampshire		0.1
New Jersey		0.2
New Mexico		0.1
New York City		0.2
North Carolina		0.1
North Dakota		0.1
Ohio		0.1
Oklahoma		0.1
Oregon		0.1
Pennsylvania		0.1
Philadelphia		0.01
Public Health Foundation Enterprises		0.2
Rhode Island		0.1
South Carolina		0.1
South Dakota		0.1
Tennessee		0.1
Texas		0.1
Utah		0.1
Vermont		0.1
Virginia		0.1
Washington		0.1
West Virginia		0.1
Wisconsin		0.2
Wyoming		0.1
<b>Cumulative Obligations, Real-Time Assessment</b>	<b>0.0</b>	<b>6.1</b>
<i>Unobligated Balances, Real-Time Assessment</i>	<i>0.0</i>	<i>0.9</i>
<b>DOMESTIC SURVEILLANCE</b>	<b>0.0</b>	<b>10.0</b>
CDC Travel and Personnel Costs associated with Domestic Surveillance		2.2
CDC Various contracts and IAAs under \$75,000 each		0.5
<b><i>CDC Contracts for Domestic Surveillance:</i></b>		
AHIP for elective activity H		1.0
Dell Marketing L.P. for Clin 1300, Optiplex 745 minitower		0.02
Emtec Federal Inc. for 19" Samsung 940Be Monitors		0.01
McKing Consulting Corporation for management consultation		0.5
Medical Staffing Network, Inc. contract for management consultation		0.1
Professional & Scientific Associates Inc. contract for international travel and logistical support services		0.2
Regents of the University of Michigan contract for longitudinal analyses		0.02
<b><i>CDC Grants for Domestic Surveillance:</i></b>		
APHL grant for National Laboratory Training Network & Management Information Systems		0.3
Children's Hospital Medical Center in Cincinnati grant for enhanced surveillance for new vaccine preventable diseases		0.3
Council of State & Territorial Epidemiologists grant for development of State-level surveillance systems and epidemiology training programs		0.3
Harvard Pilgrim Health Care, Inc. grant for Joint Initiative in Vaccine Economics (JIVE) project		0.1
Iowa State University grant for pathogenesis of infections in swine with HPAI viruses		0.4
Marshfield Clinic Research Foundation grant for rapid analysis of influenza vaccine effectiveness		0.5
Mount Sinai School of Medicine of NYU grant for development of guinea pigs as mammals to evaluate the constantly changing influenza virus' ability to transmit		0.3
University of Maryland College Park grant for development of ferrets as mammals to evaluate the constantly changing influenza virus' ability to transmit		0.1
University of Rochester grant for new vaccine preventable diseases		0.3
Vanderbilt University grant for new vaccine preventable diseases		0.3
WHO grant for addressing emerging infectious diseases		0.1
<b><i>CDC IAA's for Domestic Surveillance:</i></b>		
DOD IAA for development		1.2
GSA IAA for programming service for the NIP		0.1
USN IAA for enhanced surveillance		0.1
VA IAA for improved diagnostics for viral causes of infectious diseases		0.2
<b>Cumulative Obligations, Domestic Surveillance</b>	<b>0.0</b>	<b>8.8</b>



Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
<i>Unobligated Balances, Domestic Surveillance</i>	0.0	1.2
<b>Cumulative Obligations, Other Domestic Activities</b>	<b>125.6</b>	<b>54.8</b>
<i>Unobligated Balances, Other Domestic Activities</i>	12.4	83.2
<b>RISK COMMUNICATIONS FUNDING</b>	<b>33.0</b>	<b>18.0</b>
<i>ASPA Risk Communications Projects:</i>		
American Institutes for Research contract for Message Content Development, Mapping and Evaluation	0.7	
Applied Marine Technology Inc. contract for media tabletop exercises	0.8	
CMS & The Washington Center IAA's for staff support for pandemic communications	0.1	
Glynn Technologies contract for pandemicflu.gov developer support	0.5	
Glynn Technologies contract for pandemicflu.gov developer support (IAA with FDA)	0.3	
Hewlett Packard, Sony, Digital Asset Management System, Avid Tech., SchedulesALL, Prof. Products to support HHS-TV operations	0.9	
IGA: funds provided for state pandemic summits	1.3	
Oak Ridge Institute for Science and Education contract to exercise HHS Press Office pandemic response capabilities	0.4	
Ogilvy Public Relations Worldwide contract for strategic communications support	4.9	
Optik Communications contract for HHS-TV programming content and delivery (IAA with FDA)	2.8	
PandemicFlu.gov Equipment: Percussion license and various contracts under \$75,000	0.2	
State Pandemic Summits Travel	0.2	
WHO grant for international communications planning	0.2	
<i>CDC Risk Communications Projects:</i>		
CDC Travel and Personnel costs associated with Risk Communications	0.04	0.9
CDC Various Contracts & IAAs under \$75,000 each	1.0	
Academy for Educational Development contract for the production and distribution of public service announcements	3.0	
Academy for Educational Development media buy plan for Nat'l Influenza Vaccination Week		0.9
ASPA/HHS IAA to support coordination of risk communications activities		0.2
Booz Allen Hamilton Inc. contract for IT professional support		0.1
CNI Construction LLC. Contract to build broadcast communications capacity needs	1.7	
D.B. Consulting for management consultation and technical assistance		0.3
D.B. Consulting for message development team		1.6
Danya International contract to develop national risk communication network		0.3
Danya International contract to test cdc.gov websites and e-health products		0.1
DOE ORISE IAA for message testing	0.8	
Dept. of Treasury, FedSource IAA for contracts for message development	0.4	
DOE IAA for Oak Ridge Operations to provide staff support	0.2	
E.M.T Associates Inc. contract for continuation of quality assurance, assessment, and evaluation	0.1	
Gerald Boyd DBA DB Consulting contract for management consulting and technical assistance	0.1	
GSA IAA for Federal info system support for development of PHIRE (public health information rapid exchange)		0.3
GSA IAA to Develop and Support Decision System Specific to Influenza	0.8	
Harvard University audience research and risk communications support (cooperative agreement with ASTHO)		0.9
McKing Consulting Corp. contract for technical assistance to international partners		0.1
McKing Consulting Corp. contract for management consulting services	0.2	
McKing Consulting Corp. contract for management consulting for community continuity	0.1	
NACCHO Pilot Project, grant for Phase II for public engagement for determining vaccine priorities		0.5
National Associates Inc. contract for public affairs services	0.1	
National Public Health Information Coalition cooperative agreement to support materials review, development, distribution and best practices identification	0.4	
NCPHIC grant for development and support of a National Public Health Information Infrastructure		0.3
Northrop Grumman Cits contract to extend influenza vaccination season		0.8
Northrop Grumman contract to obtain personnel to provide specific oversight of the emergency web sites	0.4	
Northrop Grumman Information Technologies contract for technical assistance	0.2	
Pearson Government Solutions Inc. contract for pandemic surge assistance	1.5	
Phoenix Air Group, Inc. contract for air charter services and individual mission flights	0.3	
Professional & Scientific Associates Inc. contract to support Crisis and Emergency Risk Communications (CERC) trainings	1.6	

<b>Activities Funded with FY 2006 Emergency Funding:</b>	<b>FY 2006 December 2005 Supplemental Obligations</b>	<b>FY 2006 June 2006 Supplemental Obligations</b>
<b>Research Triangle Institute</b> for knowledge, attitudes and beliefs among disproportionately affected populations		0.9
<b>Science Applications International</b> contract for technical support services	0.6	
<b>Society for Public Health Education</b> grant to build capacity to conduct risk communications and public education activities	0.03	
<b>State Pandemic Influenza Summits</b>	1.5	
<b>Verizon</b> contract to create ready state call technology to respond to public during pandemic		0.5
<b>Cumulative Obligations, Risk Communications</b>	<b>28.1</b>	<b>8.6</b>
<i>Unobligated Balances, Risk Communications</i>	<i>4.9</i>	<i>9.4</i>
<b>Total Cumulative Obligations</b>	<b>3,001.1</b>	<b>1,334.5</b>
<i>Total Unobligated Balances</i>	<i>318.9</i>	<i>935.5</i>
Transfer to USAID	<u>0.0</u>	<u>30.0</u>
<b>Total HHS Pandemic Influenza Supplemental Funding</b>	<b>3,320.0</b>	<b>2,270.0</b>